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ABSTRACT 
Prior immunity to a related or unrelated pathogen greatly influences the host’s 
immune response to a subsequent infection and can cause a dramatic difference 
in disease course, a phenomenon known as heterologous immunity. Heterologous 
immunity can influence protective immunity, immunopathology and/or immune 
deviation of cytokine-producing T cell subsets. Examples of heterologous 
immunity have been well documented in mouse models, as well as during human 
infections. For example, prior immunity to lymphocytic choriomeningitis virus 
(LCMV) provides partial protection against vaccinia virus (VV), as LCMV-immune 
mice show reduced VV titers and increased survival upon lethal dose VV infection. 
Heterologous protection against VV challenge, as a result of LCMV immunity, is 
mediated by LCMV-specific CD4 and CD8 T cells, as transfer of LCMV-specific 
memory T cells can mediate this protective effect in naïve mice. The recognition of 
a single TCR with more than one MHC-peptide complex is referred to as T cell 
cross-reactivity. A VV Kb-restricted epitope a11r198 was identified to be able to 
induce cross-reactive responses from LCMV-specific CD8 T cells. During VV 
infection, LCMV-specific memory T cells that are cross-reactive to VV epitopes 
produce IFN-γ early in VV infection. IFN-γ is essential for mediating the protection 
against VV in LCMV-immune mice, as this heterologous protection is absent in 
IFN-γR-/- and IFN-γ blocking antibody-treated LCMV-immune mice. In addition to 
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protective immunity, cross-reactive LCMV-specific memory T cells and IFN-γ also 
induce an altered immunopathology during heterologous VV challenge. 
LCMV-immune mice show moderate to severe levels of inflammation of the fat 
tissue, known as panniculitis, in the visceral fat pads upon VV challenge. In 
humans, panniculitis is a painful condition, most commonly presenting as 
erythema nodosum. Erythema nodosum is a disease of unknown etiology with no 
known treatment. It may occur following intracellular bacterial and viral infections, 
and occasionally happens after vaccination with VV for smallpox. During infections 
there can be a delicate balance between the ability of immune responses to 
provide protective immunity, and the tendency to induce immunopathology. By 
using the mouse model of heterologous immunity between LCMV and VV, we tried 
to understand how the immunity to LCMV biased the balance between the 
protective immunity and immunopathology, and what effector molecules were 
responsible for the pathogenesis of panniculitis in this system. 
TNF is a pleiotropic cytokine, which is required for normal innate and adaptive 
immune responses. Its functions range from inducing proliferative responses 
including cell survival, to destructive responses such as promoting apoptosis and 
programmed necrosis. In response to inflammatory stimuli, activated 
macrophages/ monocytes produce large amounts of TNF, and upon activation, T 
cells, B cells and NK cells also produce TNF. In vitro and in vivo studies have 
shown that TNF in synergy with IFN-γ plays an important role in mediating host 
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defense against pathogens, such as Listeria monocytogenes and poxviruses in 
mice and hepatitis B virus and human immunodeficiency virus in humans. 
However, inappropriate expression of TNF often results in tissue damage. 
Considering the important role TNF plays in both host defense and mediating 
autoimmune diseases, we hypothesized that TNF was required for mediating both 
protective and pathogenic effects in the heterologous immunity between LCMV 
and VV. 
We first examined whether TNF was involved in mediating protective 
heterologous immunity. LCMV-immune mice, that were TNF-deficient as a 
consequence of genetic deletion (TNF-/-) or receptor blockade by treatment with 
etanercept (TNFR2: Fc fusion protein), were challenged with VV. These 
TNF-deficient mice showed normal recruitment and selective expansion of 
cross-reactive LCMV-specific memory CD8 T cells. They also exhibited efficient 
clearance of VV similar to LCMV-immune mice with normal TNF function. Thus, we 
concluded that neither TNF nor lymphotoxin (LT), which uses the same receptors 
as TNF, was required in mediating protective heterologous immunity against VV. 
Indeed, prior immunity to LCMV could completely compensate for the role of TNF 
in protection of naïve mice against VV infection, even under conditions of lethal 
dose inoculum. Thus, heterologous immunity may help explain why treatment of 
humans with etanercept is reasonably well tolerated with relatively few infectious 
complications. 
One of the histological characteristics of panniculitis is necrosis of adipose 
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tissue. It is known that three members in the TNF superfamily, i.e. TNF/LT, FasL 
and TRAIL are able to induce necrosis of a target cell. It is also known that TNF is 
able to induce VV-infected cells to go through necrosis, when apoptosis is blocked 
in these cells by VV protein. Furthermore, TNF and FasL have already been shown 
to be associated with some skin and fat pathology. Thus, we hypothesized that 
TNF, FasL and TRAIL were involved in the pathogenesis of panniculitis in VV 
infected LCMV-immune mice. By using blocking antibodies or genetically deficient 
mice, we demonstrated that both TNF/LT and FasL were crucial for inducing 
panniculitis. Although TNFR1 has been reported to induce programmed necrosis, 
our data indicated that TNFR2, not TNFR1, was involved in mediating tissue 
damage in the fat pads of LCMV-immune mice infected with VV. We also found that 
TNF signaled through TNFR2 to up-regulate the expression of Fas on adipocytes. 
Thus, the engagement of Fas on the adipocytes with FasL expressed on activated 
VV-specific and cross-reactive LCMV-specific CD8 T cells in the fat pads could 
lead to panniculitis. Thus, our data may identify a potential mechanism in the 
pathogenesis of human panniculitis, and may suggest a possible treatment for this 
painful disease. 
Recent reports suggest that heterologous immunity may contribute to the 
tremendous variation in symptoms between individuals, from subclinical to death, 
upon viral infection. Even in genetically identical mice, variations in 
immunopathology from none to life-threatening levels of pathology are observed in 
LCMV-immune mice during VV infection. By adoptive transfer of splenocytes from 
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a single LCMV-immune donor into two recipients, we showed that similar levels of 
pathology were generated in mice receiving the same splenocytes. However, the 
level of pathology varied among recipients receiving splenocytes from different 
LCMV-immune donors. The difference in levels of VV-induced pathology observed 
in individual LCMV-immune mice was a reflection of the private specificity of the T 
cell repertoire, which is a unique characteristic of each individual immune host. 
The goal of this doctoral thesis is to understand how heterologous immunity 
contributes to the pathogenesis of panniculitis. Our data demonstrate that TNF/LT 
and FasL directly contribute to development of panniculitis in LCMV-immune mice 
during VV infection, and suggest that anti-TNF treatment might be a useful 
treatment for diseases, such as erythema nodosum and lupus-induced acute fatty 
necrosis in humans.  
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CHAPTER I: INTRODUCTION 
CD8 T cells are a central component of host defense against intracellular 
pathogens. Following the resolution of the infection, a small proportion of the 
pathogen-specific CD8 T cells survive into memory T cells and provide long-term 
protection against re-infection with the same pathogen. Studies over the past 
decade suggest that memory T cells that are specific to antigens derived from 
previously encountered pathogens can cross-react with antigens from related or 
unrelated pathogens and alter the outcome of subsequent infections, a 
phenomenon known as heterologous immunity. Many examples of heterologous 
immunity have been reported in both murine and human systems (Welsh and 
Fujinami, 2007). For example, T cells that are specific to influenza A virus (IAV) 
epitopes can be cross-reactive to the epitopes from hepatitis C virus (HCV) and 
Epstein-Barr virus (EBV) (Clute et al., 2005; Urbani et al., 2005; Wedemeyer et al., 
2001). The cross-reactivity between IAV and HCV has been suggested to be 
associated with more severe symptoms in patients with acute HCV infection 
(Urbani et al., 2005). In mice, prior immunity to lymphocytic choriomeningitis virus 
(LCMV) can provide partial protection against subsequent infection with Pichinde 
virus (PV) or vaccinia virus (VV) (Selin et al., 1998). 
Our group has extensively studied heterologous immunity between LCMV 
and VV, and has demonstrated that both LCMV-specific memory CD8 and CD4 T 
cells are required to mediate partial protection against VV in LCMV-immune mice 
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(Selin et al., 1998). This was demonstrated by adoptive transfer of CD4 or CD8 
depleted splenocytes from LCMV-immune donors into naïve mice and challenging 
with VV (Selin et al., 1998). In addition to heterologous protection, LCMV-specific 
memory T cells mediate altered immunopathology during VV infection, as 
LCMV-immune mice develop panniculitis, in the form of acute fatty necrosis, in the 
visceral fat pads upon VV infection (Selin et al., 1998; Yang et al., 1985). The 
ability of LCMV-specific memory T cells to mediate protection and induce 
immunopathology during VV infection is dependent on IFN-γ. In the absence of 
IFN-γ either by blocking anti-IFN-γ antibodies or using IFN-γ receptor knockout 
(KO) mice, the protective and pathogenic effects of LCMV-specific memory T cells 
are completely abrogated (Selin et al., 1998). The mechanisms for the 
pathogenesis of panniculitis in this system are still not completely understood, but 
our data shown in this thesis indicate that TNF may also be involved. 
TNF is an important cytokine that regulates immune responses at many levels. 
TNF is produced by macrophages/ monocytes, T cells, B cells and NK cells upon 
activation (Aggarwal, 2003), and modulates both innate and adaptive immune 
responses (Vassalli, 1992). As shown by in vitro and in vivo studies in both mice 
and humans, TNF plays important roles in host defense against bacterial and viral 
infections (Schluter and Deckert, 2000). At the same time, TNF is also implicated 
in tissue damage and autoimmune disease. TNF is reported to be involved in the 
pathogenesis of rheumatoid arthritis (RA), Crohn’s disease, chronic heart failure 
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as well as erythema nodosum (EN), the most common from of panniculitis in 
humans (Aggarwal, 2003; Requena and Yus, 2008). 
The main interest of this thesis research is to investigate the role of TNF in 
mediating heterologous protective immunity and immunopathology in 
LCMV-immune mice challenged with VV. We hypothesized that TNF, like IFN-γ, 
would be required for both protective and pathogenic effects. Out initial approach 
to test the hypothesis was to block the effects of TNF by using anti-TNF treatment 
(etanercept, human TNFR2: Fc fusion protein) or TNF-/- mice. To determine if TNF 
was required to mediate heterologous protective immunity against VV in 
LCMV-immune mice, we compared VV levels between naïve and LCMV-immune 
mice in the presence or absence of TNF after VV challenge. We also compared 
the severities of panniculitis in LCMV-immune mice with or without TNF to reveal 
the influence of TNF on inducing panniculitis. 
 
A. T cell receptor repertoire and cross-reactive T cells 
To give the host efficient protection against a wide array of pathogens, T cell 
receptor (TCR) repertoire requires an extensive diversity. Through the processes 
of TCR gene rearrangement, editing at junctions and pairing TCR-α and β 
segments, there is potential for more than 1015 TCR generated (Fig 1.1). After 
positive and negative selection in the thymus, the diversity of TCR is reduced 
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3-100 fold. Therefore, the theoretical diversity of TCR is more than 1X1013. 
However, the estimates of the diversity of TCR in the periphery of mouse and 
human are 106-107 and 107-108 mature T lymphocytes with different sequences in 
each individual at a given time, respectively (Arstila et al., 1999; Casrouge et al., 
2000; Nikolich-Zugich et al., 2004).  
Naïve T cells are activated after contact with peptides presented by major 
histocompatibility complex (MHC) molecules in combination with co-stimulatory 
signals. Activated T cells go through programmed proliferation and become 
effector T cells. After antigen clearance, most of these effector cells undergo 
apoptosis, while a small portion survive and become memory T cells. Compared 
to naïve T cells, memory T cells have a number of advantages to provide rapid 
protection against a re-encountered pathogen. First, they are present at a higher 
frequency than naïve precursors. Second, they have a lower activation threshold 
and can respond to antigens at a lower concentration (Pihlgren et al., 1996). Third, 
they are less dependent on co-stimulatory signals (Dutton et al., 1998; Sprent and 
Surh, 2002; Welsh et al., 2004).  
Since T cell recognition of the peptide-MHC complex relies on only a few, but 
not all amino acid residues of the peptide, it is possible that one T cell can 
recognize more than one peptide bound to self MHC molecules, which is defined 
as T cell cross-reactivity (the cross-reactivity on non-self MHC molecules is not 
discussed in this thesis). Mathematical calculation suggests that a single TCR has 
the protential to recognize about 106 different peptide-MHC combinations (Mason, 
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1998). In fact, cross-reactivity is observed between peptides with similar 
sequences, with minimal similarity and with unrelated sequences (Wilson et al., 
2004). Two possible mechanisms of cross-reactivity are shown in figure 1.2. 
Molecular mimicry is a mechanism whereby a T cell uses the same receptor 
elements to interact with different peptides with large similarities in sequence and 
structure. On the other hand, a TCR is able to cross-react with a peptide with little 
or no sequence or structural similarity as a result of the conformational adjustment 
of the receptor and usage of different determinants of the TCR and peptides, 
referred as alternative recognition (Boniface et al., 1999; Daniel et al., 1998; Speir 
et al., 1998). 
A number of studies have shown evidence of cross-reactive T cell responses 
during human and murine viral infections. T cell cross-reactivity can involve 
peptides derived from the same viral protein (Anderson et al., 1992; Kulkarni et al., 
1993), different proteins encoded by the same virus (Anderson et al., 1992; 
Kuwano et al., 1991), similar proteins of different serotypes or related viruses 
(Brehm et al., 2002; Mongkolsapaya et al., 2003), and different proteins from 
unrelated viruses (Acierno et al., 2003; Clute et al., 2005; Kim et al., 2005; Nilges 
et al., 2003; Urbani et al., 2005). In the presence of cross-reactive immune 
responses, the consequence of a heterologous virus infection can be altered, a 
phenomenon termed as heterologous immunity. For example, prior immunity to 
LCMV can greatly influence the consequences of subsequent VV infection, 
resulting in rapid clearance of VV, as well as inducing immunopathology. 
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Cross-reactive CD8 T cell epitopes between LCMV and VV have been identified, 
and these cross-reactive LCMV-specific memory T cells and IFN-γ have been 
shown to be important in mediating heterologous immunity (Chen et al., 2001; 
Kim et al., 2005; Selin et al., 1998). Thus, we were able to utilize this heterologous 
immunity system to test our hypothesis that TNF was required for mediating 
heterologous protective immunity and immunopathology in LCMV-immune mice 
upon VV challenge. 
 
B. Heterologous immunity between LCMV and VV 
Many murine models have suggested that the effect of heterologous 
immunity on subsequent infections includes partial protective immunity, altered 
immunopathology and immune deviation (Welsh and Selin, 2002). One example 
of protective immunity is described in mice sequentially infected with LCMV and 
pichinde virus (PV). Three to four days after heterologous challenge, immune 
mice show a 2-200-fold reduction in viral titers, compared to immunologically 
naïve mice (Selin et al., 1998). However, the protective heterologous immunity is 
not reciprocal, as protection against PV provided by LCMV immunity is better than 
protection against LCMV provided by PV immunity (Selin et al., 1998). Similarly, 
LCMV-immune mice show reduced VV titers and increased survival upon lethal 
dose VV infection (Chen et al., 2001), while VV-immune mice are not resistant to 
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LCMV challenge (Selin et al., 1998). This lack of reciprocity may be explained by 
VV having greater potential to activate cross-reactive LCMV-specific memory T 
cells, since it is such a large virus and encodes more than 200 proteins and 
thousands of potential epitopes (Goebel et al., 1990). As demonstrated previously, 
protection against VV challenge requires both LCMV-specific CD4 and CD8 
memory T cells (Selin et al., 1998). Adoptive transfer of LCMV-specific CD4 and 
CD8 memory T cells together can mediate this protective effect in naïve mice 
during VV challenge, while deletion of either population prior to transfer leads to 
the loss of protection. LCMV-specific CD8 memory T cells are recruited to and 
accumulate in the infected peripheral tissue during VV challenge, and 
cross-reactive LCMV-specific T cells are stimulated to produce IFN-γ as early as 
day 3 post VV infection (Chen et al., 2001). By screening VV peptides with 
sequence similarity to the LCMV epitope NP205, two VV epitopes, e7r130 and 
a11r198 were identified by Cornberg et. al. (Cornberg et al., 2007). Both e7r130 and 
a11r198 have at least 30% sequence similarity to LCMV-NP205. However, only 
a11r198 induced cross-reactive CD8 T cell responses from LCMV memory CD8 T 
cells that were specific for GP118, GP34 and NP205 (Fig 1.3; Cornberg et al., 
manuscript submitted). The selective activation and expansion of these 
cross-reactive LCMV-specific memory CD8 T cells upon VV challenge led to a 
change in the hierarchies of the LCMV-specific responses. The cross-reactive 
responses elicited in different mice was distinct, and thus the skewing of LCMV 
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responses also varied between individuals (Kim et al., 2005). 
Cross-reactivity between LCMV and VV not only provides protection against 
VV, but also alters the disease pathogenesis associated with VV infection. Naïve 
mice that are infected intraperitoneally (IP) with VV have little pathology in the 
visceral fat pad, while LCMV-immune mice show moderate to severe levels of 
inflammation of the fat tissue (panniculitis) after VV infection (Selin et al., 1998). 
During VV intranasal (IN) infection, naïve mice show mainly severe pulmonary 
edema and neutrophilic infiltrate in the lung, whereas LCMV-immune mice have 
little edema but increased mononuclear infiltration and bronchiolitis obliterans 
(Chen et al., 2001). In humans, panniculitis and bronchiolitis obliterans are 
diseases of unknown etiology and sometimes occur after viral and intracellular 
bacterial infections. Similar to the protective immunity against VV, the 
immunopathology is also mediated by LCMV-specific memory T cells, as transfer 
of splenocytes from LCMV-immune mice into naïve mice could induce severe 
panniculitis after VV infection. In this condition, deletion of both CD4 and CD8 
cells was required prior to transfer to abrogate this effect, suggesting that either 
population could mediate the pathogenesis of panniculitis (Selin LK, unpublished 
data). 
Figure 1.4 summarizes the mechanism of heterologous immunity in 
LCMV-immune mice during VV challenge. VV epitopes presented by antigen 
presenting cells (APC) activate the cross-reactive LCMV-specific T cells, which 
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Figure 1.4 Model of heterologous immunity in LCMV-immune mice 
during VV infection. Some of the LCMV-specific memory T cells are 
cross-reactively stimulated by antigens from VV. This causes the 
release of IFN-γ, which further activates APCs and enhances their 
expression of MHC molecules. Together, these events antagonize viral 
replication and, at the same time, facilitate the development of 
immunopathological lesions. This model was adapted from Welsh and 
Selin 2002 Nat Rev Immunol 2: 417-426.
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produce large amounts of IFN-γ. Studies using anti-IFN-γ treatment and IFN-γR-/- 
mice, have shown that IFN-γ plays a crucial role in mediating protective immunity 
against VV and in inducing immunopathology in LCMV-immune mice (Selin et al., 
1998). The protective immunity against VV is missing in IFN-γR-/- LCMV-immune 
mice, and　 the levels of panniculitis are diminished in anti-IFN-γ treated or 
IFN-γR-/- LCMV-immune mice. 
 
C. The effect of private specificity on heterologous immunity 
The hierarchies of epitope-specific T cell responses to a given pathogen are 
often similar in genetically identical mice. One example is that LCMV infection of  
naïve C57BL/6 mice generates a CD8 T cell response to LCMV epitopes in a 
common hierarchy, as the response is co-dominated by NP396 and GP33/34 
responses, while GP276, NP205 and GP118 responses are subdominant (Kim et al., 
2005). Similar hierarchies of LCMV-specific responses are used in most of 
LCMV-infected naïve C57BL/6J mice. This is a form of public specificity in TCR 
repertoire. However, at the clonal level the T cell response against a given epitope 
differs between individuals, as TCR with different CDR3 amino acid sequences 
are used in the epitope-specific response by different individuals, these leading to 
private specificity of TCR repertoire (Welsh, 2006). The most comprehensive 
explanation for this individual variation in TCR usage by an epitope-specific 
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response is the difference in the peripheral T cell pool generated in each host. 
The independent and random rearrangement of DNA segments generates a TCR 
repertoire with wide variety in an individual. The potential diversity of peripheral 
TCR repertoire is ~1013 for mice and ~1016 for human, and the total number of 
unique T-cell clonotypes is ~106 for mice and ~107 for humans (Nikolich-Zugich et 
al., 2004; Venturi et al., 2008). Differences in expressed TCR repertoires are 
expected, even between genetically identical animals. In fact, an analysis of naïve 
T cells in individual mice of the same inbred strain shows that the naïve repertoire 
is mostly non-overlapping in distinct animals (Bousso et al., 1998). Random 
stochastic encounters of T cells with antigen also cause differences in TCR usage 
for a specific response. After transfer of naïve T cells derived from a single donor, 
two recipients generate different TCR repertoires in response to the same peptide 
stimulation (Attuil et al., 2000). Thus, differences in the peripheral naïve TCR 
repertoires and the random process of antigen-T cell engagement both contribute 
to private specificity in antigen-specific TCR repertoires (Welsh, 2006). 
After heterologous challenge, the frequency of memory T cells that are 
specific for previously encountered antigen is significantly decreased (Selin et al., 
1999). The mechanisms for the decreased frequency of memory T cells include 
dilution by the accumulation of new effector cells, and the apoptotic death of about 
one third of the pre-existing memory T cells that are not cross-reactive to the 
heterologous pathogen. However, after a transient attrition, a small subset of 
memory T cells that cross-react with the current infecting pathogen expand and 
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give rise to a skewed hierarchy in the T cell response specific to the original 
antigen. In PV challenged LCMV-immune mice, the T cell response against 
LCMV-NP205, which is cross-reactive to PV-NP205, shows a dramatic increase, 
while the normally dominant LCMV-NP396 and GP33 responses are remarkably 
decreased (Brehm et al., 2002). Although an enhancement of NP205 responses 
was shown in all LCMV-immune mice challenged with PV, individual variations in 
magnitude as well as TCR usage were found (Cornberg et al., 2006). This 
variation is a reflection of private specificity of the memory T cell repertoire. 
Another example of private specificity is the unpredictable expansion of 
LCMV-specific CD8 T cells in LCMV-immune mice infected with VV (Chen et al., 
2001; Kim et al., 2002; Kim et al., 2005). As shown in Figure 1.3, cross-reactivity 
between LCMV and VV is more complex than cross-reactivity between LCMV and 
PV. The proliferation of cross-reactive T cells in response to VV challenge is not 
always the same in different mice. Indeed, 50% of VV-infected LCMV-immune 
mice showed selective expansion of LCMV-NP205 responses, and 15% and 12% 
of mice showed an increase in GP33/34- and GP118-specific responses, 
respectively (Kim et al., 2005). To understand the cause of this variation, a 
modified adoptive transfer technique was used (Fig 1.5). Naïve mice receiving 
splenocytes derived from a single LCMV-immune donor exhibited similar 
expansion of LCMV-specific responses, while mice receiving different donor cells 
exhibited unique responses (Kim et al., 2005). Thus, differences in the VV-induced 
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Figure 1.5 Experimental design used for studying the role of private 
specificity in the pattern of cross-reactivity. CFSE-labeled LCMV
immune donor cells derived from a single donor were transferred into 
multiple hosts, which were infected with VV. This graph was adapted from 
Kim SK 2005 J Exp Med 201: 523-533. 
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patterns of cross-reactivity among LCMV-immune mice are determined by the 
private specificity of the memory T cells within the individual host.  
In a phenomenon similar to the variations in cross-reactive responses induced 
in LCMV-immune mice by VV infection, the levels of panniculitis generated in these 
mice are also different between individuals. The severity of panniculitis varies from 
none to life-threatening levels. Panniculitis in VV-infected LCMV-immune mice is 
mediated by cross-reactive LCMV-specific memory T cells. Therefore, we 
hypothesized that the variations in levels of panniculitis were also influenced by 
private specificity.  
 
D. Panniculitis: inflammation of fat tissue 
Panniculitis is a group of diseases that involve inflammation of adipose 
tissues (Requena and Yus, 2001). It presents as single or multiple crops of tender 
nodules in fat tissue. Histological analysis shows fat cell necrosis, infiltration of 
inflammatory cells and fat-filled macrophages in acute panniculitis. Panniculitis 
may occur in both cutaneous and visceral fat tissue, and may result from a variety 
of conditions. Usually, panniculitis without systemic disease is due to trauma or 
cold. Panniculitis with systemic disease includes lupus, scleroderma, lymphomas 
and pancreatitis (Requena and Yus, 2001). There are several forms of cutaneous 
panniculitis, including erythema nodosum (EN) and erythema nodosum leprosum 
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(Requena and Yus, 2001).  
Panniculitis in the form of acute fatty necrosis occurs in LCMV-immune mice 
after VV infection. It is histologically characterized by the infiltration of inflammatory 
cells and necrosis of fat cells (Fig 1.6) (Selin et al., 1998; Yang et al., 1985), which 
is quite similar to human EN. EN is the most common form of human panniculitis 
(Requena and Yus, 2008). It presents with painful, tender, erythematous nodules 
usually 1-5 cm in diameter, and is most commonly located on the anterior portion of 
the lower legs, arms and soles. The lesions may be associated with fever, malaise, 
and joint pain. The etiology of EN is unknown, but it is mostly associated with 
fungal diseases, infectious mononucleosis, intracellular bacterial and viral 
infections and inflammatory bowel disease. It has also been reported that EN may 
occur after vaccination, including with VV which is used to vaccinate against 
smallpox (Gaertner et al., 2004). When the underlying disease is identified, 
patients usually respond well to the treatment. However, in a significant portion of 
EN, an association can not be found (Requena and Yus, 2008). In such situations, 
anti-inflammatory drugs and cortisone are used as standard treatment. But it is 
common that EN patients fail to respond to this treatment. 
In the mid 1960s, thalidomide had been reported to have dramatic efficacy in 
treatment of erythema nodosum leprosum, another pathologic variant of 
panniculitis (Deng et al., 2003). Although the mechanism of action for thalidomide 
is still not completely clear, it has been reported that thalidomide selectively 
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inhibits the production of TNF in human peripheral monocytes (Sampaio et al., 
1991) by accelerating the degradation of TNF mRNA (Moreira et al., 1993). 
Another study done in mice suggests that Thalidomide reduces TNF production 
and antigen presentation by Langerhans cells (Deng et al., 2003). Recently, Boyd 
reported that a patient suffering from EN with unknown association had no 
response to standard therapeutic reagents, but significantly improved after 
receiving anti-TNF therapy (Boyd, 2007). Thus, these data suggest that TNF may 
play a role in EN.  
In this thesis, we use the mouse model of heterologous immunity between 
LCMV and VV to test if TNF is involved in mediating panniculitis in LCMV-immune 
mice infected with VV. 
 
E. “Cross-talk” between adipose tissue and immune system 
Historically, fat cells were believed to be just containers for energy, which was 
released when the body required it. This paradigm was challenged when 
Hotamisligil first demonstrated that fat cells could produce TNF, a very important 
cytokine for both normal immune responses and autoimmune diseases 
(Hotamisligil et al., 1993). Production of TNF by fat tissue is responsible for the 
induction of insulin resistance, as neutralization of TNF can increase sensitivity to 
insulin in obese-diabetic animals (Hotamisligil et al., 1993). This study suggested 
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that adipose tissue has significant biological functions.  
Fat cells can produce many different cytokines and adipokines, in addition to 
TNF. These cytokines and adipokines are involved in the induction of fat tissue 
inflammation, type 2 diabetes and cardiovascular disease (Powell, 2007). It has 
been suggested that TNF produced locally within adipose tissue is sequestered 
by the large amount of TNF receptors (TNFR) expressed in the tissue 
(Mohamed-Ali et al., 1999). However, TNF can induce adipocytes to express 
other cytokines, including IL-6 and leptin, through which the fat tissue can 
“cross-talk” to the immune system. Leptin, one of the most studied cytokines in 
adipocytes, plays a regulatory role in both innate and adaptive immunity 
(Matarese et al., 2007). In innate immunity, leptin elevates the activation of 
macrophages and increases the production of pro-inflammatory cytokines, such 
as TNF, IL-6 and IL-12. For adaptive immunity, leptin is important for thymic 
homeostasis during ontogeny, and for lymphocyte activation in the periphery. 
Furthermore, leptin can also polarize Th1 cytokine production and negatively 
regulate the proliferation of regulatory T cells, which may explain the association 
of leptin with some autoimmune diseases (Matarese et al., 2007). 
Fat cells are also responding to cytokines, including TNF. TNF regulates the 
expression of some adipose-specific genes, including GLUT4 and free fatty acid, 
which are important for inducing insulin resistance (Ruan et al., 2002). It also 
modulates the metabolism of adipocytes, such as mediating cachexia, a wasting 
syndrome (Beutler and Cerami, 1986). As fat cells increase in size, TNF 
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expression is correspondingly increased, which in turn limits the growth of these 
cells. TNF negatively regulates adipose tissue mass by blocking the differentiation 
of pre-adipocytes, de-differentiating mature adipocytes and inducing apoptosis of 
adipocytes and pre-adipocytes (Coppack, 2001). Visceral pre-adipocytes are 
more sensitive to TNF-induced apoptosis than subcutaneous pre-adipocytes 
(Niesler et al., 1998), and the apoptosis of adipocytes induced by TNF is believed 
to be transduced by TNF receptor (TNFR) 1 (Hube and Hauner, 1999).  
In this thesis, we are interested in the effect of TNF on inducing fat tissue 
damage during VV infection in LCMV-immune mice. We test how TNF mediates 
the necrosis of the fat cells, and which receptor is involved.  
 
F. TNF and immune response 
Inflammatory stimuli, such as IFN-γ and lipopolysaccharide (LPS), stimulate 
TNF production by activated macrophages/ monocytes, which interacts with 
TNFR1 (expressed on virtually all cells in the body) and TNFR2 (expressed on 
immune cells, endothelia cells and adipocytes) (Aggarwal, 2003; Hotamisligil et 
al., 1997) and induces a variety of biological effects (Fig 1.7). TNF can stimulate 
macrophages and monocytes to further increase the production of TNF by these 
cells (Descoteaux and Matlashewski, 1990; Philip and Epstein, 1986). In addition 
to macrophages and monocytes, T cells, B cells and NK cells also produce TNF 
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Figure 1.7 Multiple actions of TNF. In response to inflammatory stimuli,
activated macrophages produce TNF, which binds to its receptors and
causes a variety of reactions. This figure was adapted from Bazzoni and
Beutler 1996 N. Engl. J. Med. 334:1717-1725. 
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upon activation (Aggarwal, 2003). Since TNF receptors are present on most 
immune cells, TNF affects the immune system profoundly by regulating both 
innate and adaptive immunity. 
Innate immunity. TNF can increase inflammation by acting on endothelial 
cells to induce the production of other pro-inflammatory cytokines, such as IL-1 
(Beutler and Cerami, 1989), IL-6 (Jirik et al., 1989), IL-8 (Gimbrone, Jr. et al., 1989) 
and GM-CSF (Seelentag et al., 1987). It can also increase the migration of 
leukocytes into sites of inflammation by inducing changes in the shape of 
endothelial cells, increasing the permeability of vascular endothelium (Beutler and 
Cerami, 1989), and enhancing the expression of adhesion molecules, such as 
intracellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 
(VCAM-1) (Doukas and Pober, 1990; Osborn, 1990). A few hours after intradermal 
injection of small amounts of TNF, mononuclear cells accumulate at the site 
(Munro et al., 1989). TNF also elevates the expression of MHC class I molecules 
on endothelial cells, which increases the antigen presentation to CD8 T cells to 
facilitate detection and elimination of target cells by antigen-specific CD8 T cells 
(Doukas and Pober, 1990). TNF exerts an important role in activating 
macrophages and monocytes. In synergy with IFN-γ, TNF increases the 
cytotoxicity of macrophages, which is important for protection against bacterial 
infection (Liew et al., 1990). Finally, NK cells are also influenced by TNF. Upon 
TNF stimuli, NK cells increase the expression of CD25 (high affinity IL-2 receptor) 
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and increase their cytolytic activity (Ostensen et al., 1987). 
Adaptive immunity. TNF modulates antigen-specific T cells at multiple points 
during the response. First, TNF regulates antigen presentation by optimizing the 
function of dendritic cells (DC). DCs reside in many organs and tissues, and fulfill 
a immune surveillance function by capturing, processing and presenting antigens 
to lymphocytes. As shown by Yu et al., the coordinated signals from TNF and 
other TNF superfamily members are required for optimized maturation of dendritic 
cells (Yu et al., 2003). The cooperation of TNF with CD40L and RANKL, members 
of TNF superfamily, maximizes the ability of DC to induce virus-specific cytotoxic 
T lymphocytes responses.  
Second, TNF also directly modulates the activation of T cells by providing 
co-stimulatory signals. Although resting T cells do not express TNFR, after 
activation by TCR engagement in the presence of secondary signals, activated T 
cells increase the expression of TNFR, especially TNFR2 (Zheng et al., 1995). 
The proliferation of activated T cells is substantially augmented by adding 
exogenous TNF to T cell cultures, and dramatically diminished in the presence of 
neutralizing antibody against TNF (Pimentel-Muinos et al., 1994). TNFR2 serves 
as a co-stimulator during T cell activation to increases IL-2 production by T cells, 
and help T cell survival by inducing the expression of anti-apoptotic molecule, 
Bcl-xL (Kim and Teh, 2004).  
Third, TNF induces T cell death during the contraction phase of effector T 
cells. As shown by Singh and Suresh, the decline of CD8 T cell response against 
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LCMV is significantly impaired in TNF-/- mice long after the clearance of virus 
(Singh and Suresh, 2007). TNF-induced CD8 T cell death is independent of Fas, 
as it has different kinetics as compared to Fas-induced apoptosis, and it can not 
be abrogated by neutralizing antibody blockade or defective mutation (lpr) of Fas 
(Sarin et al., 1995; Zheng et al., 1995).  
Lymphoid tissue structure. In addition to multiple effects on inflammation and 
lymphocyte activation, differentiation and death, TNF and TNF superfamily 
members are important for development and organization of peripheral lymphoid 
tissues. Mice that are lacking lymphotoxin (LT), which uses the same receptors as 
TNF, have no lymph nodes or gut-associated lymphoid tissues, Peyer’s patches 
(PP). The architecture of the spleen is also severely disturbed in these mice (De 
et al., 1994). Compared to LT-/- mice, TNF-/- and TNFR1-/- mice have relatively 
normal development of lymphoid tissues. Although the predominant signals are 
transduced by LT, it was shown by Pasparakis and colleagues that TNF signaling 
through TNFR1 may be required for the full development of normal PP. The PP 
formed in TNF-/- and TNFR1-/- mice are fewer in number and smaller than the 
ones in wild type (WT) mice, and B cell follicles and follicular dendritic cells (DC) 
networks are absent in the lymph node and PP in these mice (Pasparakis et al., 
1997). 
Therefore, TNF modulates the immune system at a variety of levels, including 
inflammation, cell trafficking, activation, differentiation, proliferation, death and the 
development of lymphoid tissue. 
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G. TNF and infection 
Considering the many effects TNF has on regulating immune responses, 
there is no surprise that TNF has a key role in mediating host defense against 
pathogens (Schluter and Deckert, 2000).  
Bacterial infection. An essential role for TNF in immunity to bacterial infection 
has been demonstrated by using blocking antibodies and genetically deficient 
animals. As mentioned above, TNF enhances the cytotoxic pathway of 
macrophages, including the production of nitric oxide, which is toxic to bacteria 
(Vassalli, 1992). For example, in Listerial monocytogenes infected mice, the 
signaling of TNF through TNFR1 is absolutely required for controlling bacterial 
infection, since the absence of either TNF (Havell, 1989; Nakane et al., 1988) or 
TNFR1 (Pfeffer et al., 1993; Rothe et al., 1993) leads to uncontrolled bacterial 
growth and rapid death due to the failure of the innate immune system. TNF is 
also important to control infection with mycobacteria. Neutralizing TNF greatly 
impairs the formation of granulomas, which contain macrophages, and results in 
bacterial overgrowth and death of the hosts (Flynn et al., 1995; Garcia et al., 1997; 
Kindler et al., 1989). There is evidence in humans that anti-TNF leads to 
increased risk of reactivation of tuberculosis (see Discussion). 
Viral infection. In vitro studies have suggested a direct antiviral effect of TNF, 
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e.g. treatment with recombinant TNF increases resistance to viral infections in 
some cell types, especially in the presence of IFN-γ (Mestan et al., 1986; Wong 
and Goeddel, 1986). Additional studies have demonstrated that TNF, mostly in 
synergy with IFN-γ, provides antiviral activity in vivo. For instance, during hepatitis 
B virus infection, TNF and IFN-γ mediate the clearance of the virus (Guidotti et al., 
1996). A polymorphism of the TNF promoter, which may influence the production 
of TNF, has shown to be associated with defective viral clearance and 
establishment of chronic HBV infection (Hohler et al., 1998). TNF also interferes 
with the infection of human immunodeficiency virus type 1 (HIV-1), as it can block 
the entry of HIV-1 by directly or indirectly down-regulating the expressions of CD4 
and CCR5, the receptors for HIV-1 (Di et al., 1998; Herbein et al., 1996; Karsten 
et al., 1996). 
In this thesis, my primary focus is on the antiviral activity of TNF during VV 
infection. Localized expression of TNF can accelerate the clearance of VV 
(Lidbury et al., 1995; Ruby et al., 1997; Sambhi et al., 1991). It has also been 
shown that both TNFR1 and TNFR2 are required for mediating protection against 
VV and ectromelia virus (EV), another poxvirus. Both TNFR1-/- and TNFR2-/- mice 
show impaired clearance of VV and EV, and increased susceptibility to lethal EV 
infection (Chan et al., 2003; Ruby et al., 1997). To counteract the antiviral effect of 
TNF, VV encodes proteins to disrupt TNF-signaling. For example, some strains of 
VV encode soluble and cell-surface TNFR, which contributes to the virulence of 
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the virus (Reading et al., 2002). The Western Reserve (WR) strain of VV, which 
we are using in our studies, encodes a protein (B13R) that blocks apoptosis 
induced by TNF and anti-Fas antibodies (Kettle et al., 1997). TNF overcomes the 
blocking-effects of VV by mediating another pathway, which induces necrotic-like 
cell death, to eliminate the infected cells (Li and Beg, 2000). Considering its 
important immune regulatory and antiviral roles, we tested the effect of TNF on 
heterologous immunity. This thesis research directly tested the importance of TNF 
in protecting against VV by comparing VV loads of WT and TNF-deficient (TNF-/- 
or etanercept-treated) naïve mice after VV infection. We also examined the role 
for TNF in mediating heterologous protective immunity by using the mouse 
heterologous immunity model between LCMV and VV.  
 
H. Association of TNF and TNFR with autoimmune diseases 
Despite the important role TNF has in the immune system, inappropriate 
expression of TNF can be detrimental to the host. TNF has been implicated in 
many autoimmune diseases. Besides erythema nodosum, type II diabetes 
mellitus is thought to be associated with TNF production. As mentioned above, fat 
cells produce TNF, which in turn regulates the metabolism of fat cells. This 
cytokine has been shown to induce insulin resistance, as neutralization of TNF 
can increase the insulin sensitivity in rats (Hotamisligil et al., 1993), and TNF-/- 
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mice are protected from obesity-induced insulin resistance (Uysal et al., 1997). 
TNF has also been reported to be involved in the pathogenesis of RA and Crohn’s 
disease, a type of inflammatory bowel disease, and anti-TNF drugs have been 
approved for the treatment of Crohn’s disease and RA in human (Aggarwal, 
2003).  
Additionally, associations between a polymorphism of TNF receptors and 
human autoimmune diseases have been reported. A study of several families with 
dominantly inherited auto-inflammatory syndromes suggested an association of 
TNFR1 mutants with these syndromes. These TNFR1 mutants have impaired 
cleavage following stimulation, resulting in high levels of membrane-bound but 
diminished soluble form of TNFR1, which is important for down regulating TNF 
signal (McDermott et al., 1999). A polymorphism in TNFR2 has been shown to be 
associated with familial RA (Dieude et al., 2002) and systemic lupus 
erythematosus (Komata et al., 1999; Morita et al., 2001). This polymorphism 
(TNFR2 196R), with a methionine replaced by an arginine, is a more effective 
transducer for the signal of TNF (Morita et al., 2001).. 
As TNF has been implicated in the pathogenesis of EN, a form of panniculitis 
in humans, we tested here whether TNF was responsible for the generation of 
panniculitis in VV-infected LCMV-immune mice. We also explored the pathway 
that TNF used to induce this pathology. 
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I. Thesis objectives 
During VV infection, LCMV-immune mice show rapid viral clearance, but 
develop panniculitis on the visceral fat pads. According to previous studies, TNF 
may play a role in host defense against VV, and it has been suggested to be 
involved in the pathogenesis of EN, the most common form of panniculitis in 
humans. Thus, our hypothesis is that TNF, like IFN-γ, is required for mediating 
both heterologous protection and panniculitis in LCMV-immune mice infected with 
VV. My thesis is presented in three parts: 
Chapter III : Heterologous immunity can abrogate the requirement for TNF in 
protection against VV. 
This chapter examines the role of TNF in mediating protection 
against VV in both naïve and LCMV-immune mice by comparing VV 
titers between VV-infected WT and TNF-deficient (TNF-/- or 
etanercept-treated) mice. 
Chapter IV : Individual variations in the pathogenesis of viral infection are 
determined by private specificity. 
By transferring the same population of splenocytes from one 
LCMV-immune donor into two naïve recipients, this chapter 
demonstrates the major determinant of individual variations in the 
pathogenesis of panniculitis in LCMV-immune mice during VV 
infection. It also provides an approach to minimize the influence of 
 
32 
individual variation on the prediction of the results from 
immunopathology studies in the next chapter.  
Chapter V : TNF/LT and FasL mediate the pathogenesis of panniculitis in 
LCMV-immune mice during VV infection. 
This chapter illustrates whether TNF and LT induce the necrosis of 
fat tissues in LCMV-immune mice during VV challenge, by 
comparing the levels of panniculitis between TNF-deficient mice and 
WT controls. 
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CHAPTER II: MATERIALS AND METHODS 
A. Mice 
Male C57BL/6 (B6, H2b) mice, TNFR1-/- mice (B6.129-Tnfrsf1atm1Mak/J), 
TNFR2-/- mice (B6.129S2-Tnfrsf1btm1Mwm/J), IFN-γR-/- mice (B6.129S7- 
Ifngr1tm1Agt/J) and FasL-deficient (gld) mice (B6Smn.C3-Faslgld/J) were purchased 
from The Jackson Laboratory (Bar Harbor, ME). Ly5.1 mice (B6.SJL-Ptprca) were 
purchased from Taconic Farms. TNF-/- mice (B6; 129S6-TNFtmlgkl) originally from 
Jackson Laboratory were backcrossed onto B6 mice using MAX-BAX speed 
congenics until the mice were 99% B6 background (Charles River Laboratories, 
Inc., Wilmington, MA). All mice were maintained under specific pathogen-free 
conditions within our animal colony. 
 
B. Viruses 
LCMV is a RNA virus in the Old World arenavirus family. The Armstrong strain 
of LCMV was propagated in BHK21 baby hamster kidney cells (Selin et al., 1994). 
Vaccinia virus (VV) is a DNA virus in the poxvirus family. The WR strain of VV was 
propagated in either NCTC-929 cells or Hela cells (Selin et al., 1994).  
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C. Infection protocol and blocking treatments for TNF and 
TRAIL 
For LCMV-immunization, mice were inoculated IP with 5 X 104 PFU of LCMV 
Armstrong. In most experiments, immune mice were challenged with 1 X 106 PFU 
of VV IP six weeks after immunization, when the immune system had returned to 
homeostasis. For experiments using gld mice, all the mice were immunized with 
LCMV at 4 weeks of age and challenged with VV four weeks later. For experiments 
using TNF-/- mice, both KO mice and B6 controls were challenged with 7.5 X 105 
PFU VV IP. For the mortality test in the IP model, various VV doses were used for 
different groups, as indicated in the context. For the mortality test in the IN model, 
metofane-anesthetized mice were immunized with 5 X 105 PFU LCMV Armstrong 
IN, and 6 weeks later both immune and non-immune mice were challenged 4 X 104 
PFU VV IN.  
For experiments blocking TNF and LT in vivo, 2 days before infection, mice 
were treated IP with either 100μg of TNFR2:IgG fusion protein (etanercept, 
Immunes Corporation, Thousand Oaks, CA, a gift from Dr. Dale Greiner) or 100μg 
of goat anti hIgG-Fc (Fitzgerald, Concord, MA) , as a control. For TRAIL blockade, 
mice were given 250μg of anti-mouse TRAIL antibody (109308, Biolegend) IP at 
day -1 and day 3 of VV infection. 
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D. Synthetic peptides 
LCMV-specific peptides: NP396-404 (FQPQNGQFI; Db binding), GP33-41 
(KAVYNFATC; Db binding), GP276-286 (SGVENPGGYCL; Db binding), 
NP205-212 (YTVKYPNL; Kb binding), GP118-125 (ISHNFCNL; Kb binding); 
VV-specific peptides: B8R20-27 (TSYKFESV; Kb binding), E7R130-137 
(STLNFNNL; Kb binding) and A11R198-205 (AIVNYANL; Kb binding) were 
purchased from BioSource International, and were purified with reverse 
phase-HPLC to 90% purity. 
 
E. Plaque assay 
VV loads in fat pads and testes were titrated on ATCC vero cell monolayers 
using a 3-day plaque assay. Tissues, after extraction from VV-infected mice, were 
put in 1mL complete RPMI 1640 medium (GIBCO, Gaithersburg, MD). 
Homogenized tissues were centrifuged at 2,000rpm for 20 minutes at 4°C, and 
supernatant stored at -80°C. Frozen aliquots were thawed on the day of plaque 
assay (day 0) and immediately applied on vero cells grown in 6-well plates (Costar, 
Cambridge, MA). Ten-fold serial dilutions of tissue homogenate (100 μL) were 
added onto the cells in 1 mL complete MEM medium (GIBCO, Gaithersburg, MD) 
containing 10% heat-inactivated FBS, 50units/mL penicillin and 50μg/mL 
streptomycin. Cells were incubated at 37°C for 90 min. Then 4 mL overlay mixture 
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(1:1 mixture of 1% SeaKem® ME agarose (FMC, Rockland, ME) and EMEM 
(Lonza, Walkersville, MD) containing 10% FBS) was overlaid onto the cells. 
Plates were kept in a 5% CO2-humidified atmosphere at 37°C for two days. At day 
2 of assay, the plates were stained with 2 mL of the overlay mixture containing 0.1% 
neutral red (Sigma). Plaques were counted on day 3. Virus titers were shown as 
log10 of PFU per whole organ. Results were expressed as the geometric mean 
titers, i.e., the arithmetic averages of the logs for four or five separate animals 
titrated for virus individually ± SEM.  
 
F. Preparation of leukocytes 
Spleens were harvested and ground between the frosted ends of two 
microscope slides. The cell suspension was then passed through a fine nylon 
mesh to obtain single cell suspension. Cells from the peritoneal cavity were 
collected by lavaging with 10 mL cold RPMI 1640 medium. Infiltrating leukocytes 
were isolated from fat pads by mincing and digesting with 0.5 mg/ml type II 
collagenase (Sigma-Aldrich, St. Louis, MO) and 100 U/ml type I DNase 
(Sigma-Aldrich) in HBSS buffer (GIBCO, Gaithersburg, MD) plus 10% heat 
inactived FBS for 45 minutes at 37°C. The digest mixture was then centrifuged at 
2,000 rpm for 10 minutes. Cell pellets were suspended in RPMI and passed 
through mesh to obtain single cell suspensions, which then were layered over 
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lympholyte-M (Cedarlane Labs, Hornby, Canada) and centrifuged at 2,000 rpm for 
20 minutes at room temperature. The mononuclear band was collected and 
washed with RPMI 1640 medium to remove lympholyte-M. Contaminating 
erythrocytes were removed from the leukocyte preparations by treatment with 0.84% 
NH4Cl. 
 
G. Flow cytometry and intracellular IFN-γ staining 
Isolated cells (2X106) were incubated in 96-well plates (5h; 37°C) with 5 μM 
synthetic peptide, 10 U/mL human rIL-2 (BD Bioscience), and 0.2 μL of GolgiPlug 
(BD Bioscience). Cells were then washed in FACS buffer (PBS, 2% FCS, and 0.1% 
NaN3), blocked with anti-Fc antibody (2.4G2, BD Biosciences) for 15 minutes at 
4°C. After two washes with FACS buffer, cells were incubated (30 min; 4°C) with a 
combination of fluorescently labeled mAbs specific for CD44 (IM7, FITC, BD 
Bioscience), CD8α (53-6.7, PerCP-Cy5.5, BD Bioscience) and CD45.1 (A20, 
PE-Cy7, eBioscience). Cells were then fixed and permeabilized with BD 
Cytofix/CytopermTM solution (51-2090KZ, BD Bioscience) for 20 minutes at 4°C, 
and washed with 1X perm/washTM solution (51-2091KZ, BD Bioscience). To detect 
cytokine production, cells were stained with mAb specific for IFN-γ (XMG1.2, APC, 
BD Bioscience) and TNF (MP6-XT22, PE, BD Bioscience). The samples were 
analyzed using a BD Biosciences LSR II and FlowJo software. The total number of 
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epitope-specific CD8 T cells was calculated by multiplying the percentage with the 
total cell yield from individual tissue. For most experiments, the lymphocytes 
isolated from peritoneal cavity and fat pads were pooled for each group, due to the 
low cell yield from these organs. 
 
H. Adoptive transfer of LCMV-immune splenocytes 
Ly5.1 mice were inoculated IP with 5X104 PFU of LCMV Armstrong and were 
considered immune more than 6 weeks after infection. For paired adoptive transfer 
experiments, whole splenocytes from one Ly5.1 LCMV-immune mouse were 
equally split and adoptively transferred intravenously (IV) into two hosts (two Ly5.2 
C57BL/6J mice or one Ly5.2 C57BL/6J mouse and one Ly5.2 TNFR-/- mouse) in a 
200-μL volume of HBSS. For pooled adoptive transfer experiments, pooled 
splenocytes from five or more Ly5.1 LCMV-immune mice were equally transferred 
IV into four or five Ly5.2 C57BL/6J mice in a 200-μL volume of HBSS. One day 
post transfer, all recipients were challenged IP with 1 X 106 PFU WR strain of VV. 
 
I. CFSE labeling 
Splenocytes from immune donor mice were harvested and isolated as 
described above. In some experiments, the donor immune cells were labeled with 
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CFSE by suspending at 2.0 x 107 cells/ml in HBSS containing 2 µM CFSE 
(Molecular Probes) and incubated for 12 min at 37°C. After incubation, donor cells 
were washed twice with HBSS. 
 
J. Scoring the levels of panniculitis 
The level of panniculitis was score visually based on the severity of disease 
from level 0 to 8. Levels 1 and 2 represent very mild to mild disease with a few 
white necrotic spots on one or both lower abdominal fat pads; levels 3 and 4 
represent mildly moderate and moderate with larger patches of necrosis of the 
lower abdominal fat pads and extension into the upper left quadrant fat pad around 
the spleen; levels 5 and 6 represent moderately severe to severe with very 
extensive large patches of necrosis throughout visceral fat pads as well as the 
splenic fat pad; level 7 represents very severe disease with such severe fatty 
necrosis that the organs are adherent to each other; and level 8 represents 
moribund with the fatty necrosis so severe that the animal can not survive. 
 
K. 3T3-L1 cell line and TNF stimulation 
3T3-L1 fibroblasts were maintained in 150-mm tissue culture dishes by 
seeding at a density of 750,000-1,000,000 cells per dish. Cells were grown to 
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confluence in complete media (high glucose DMEM (Gibco) containing 10% FBS, 
50units/mL penicillin and 50μg/mL streptomycin) and kept in a 10% 
CO2-humidified atmosphere at 37°C. Medium was changed every 2-3 days. Two 
days after the fibroblasts achieved confluence, differentiation to adipocytes was 
induced by incubating the cells for 3 days in 25mL complete media containing 
4μg/mL insulin (Sigma), 0.25μM dexamethasone (Sigma) and 0.5mM 3-isobutyl 
1-methylxanthine (Sigma). Then media was replaced with regular complete media. 
Four days after differentiation, cells were harvested and resuspended in 50mL 
complete media. 1mL of resuspended cells were distributed per well of a 12-well 
plate. After 48 hours, the adipocytes were pretreated for one hour with 1μg/mL 
hamster IgG (20003, Alpha Diagnostics international Inc, San Antonio, TX), 
TNFR1 antagonistic antibody (MAB430, R&D system) or TNFR2 antagonistic 
antibody (113301, Biolegend), followed with 24-h stimulation with 5ng/mL TNF 
(654245, Calbiochem). 
 
L. Isolation of RNA and quantitative real-time PCR 
RNA isolation was performed according to the RNeasy mini kit protocol 
(Qiagen). The concentration and the purity of the RNA were determined by 
measuring the absorbance at 260/280 nm. cDNA was synthesized using 1μg of 
RNA and the iScript cDNA synthesis kit (Bio-rad) for a 20-μL reaction volume. For 
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real-time PCR, 1 μL of synthesized cDNA was put into one well of a 96-well plate 
for detections of Fas mRNA (forward primer 5’-TAT CAA GGA GGC CCA TTT 
TGC-3’ and reverse primer 5’-TGT TTC CAC TTC TAA ACC ATG CT-3’); and DR5 
mRNA (forward primer 5’-TCT GCC AGT CAT GCT CTA ACT G-3’ and reverse 
primer 5’-CTG AGT CTT GCC AGG TTC CGT GT-3’). The expression of 
hypoxanthine-guanine phosphoribostyltransferase (HPRT) did not change over a 
24-hour period TNF stimulation, so it was used as an internal loading control 
(forward primer 5’-TCA GTC AAC GGG GGA CAT AAA-3’ and reverse primer 
5’-GGG GCT GTA CTG CTT AAC CAG-3’). 10 pmol of forward and reverse primer 
was added to each well along with DNase/RNase free water and 25 μL of iQ SYBR 
Green Supermix (Bio-rad) for a 50-μL final volume. Samples were run on the MyIQ 
Real time PCR System (Bio-rad). Relative gene expression was determined by 
using the 2-ΔΔCT method (Livak and Schmittgen, 2001). The real-time PCR 
program was: 95°C for 3 minutes, followed by 95°C for 15 seconds, 60°C 30 
seconds and 72°C 30 seconds for a total of 40 cycles, and a 5-minute incubation 
at 72°C. 
 
M. Histology analysis 
Histology was done on fat pads isolated at 6 days after VV challenge. 
Samples were fixed in 10% neutral buffered formaldehyde and then 
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paraffin-embedded. Tissue sections (5μm) were stained with hematoxylin and 
eosin by Diabetes and Endocrinology Research Center Morphology Core 
Laboratory (DERC lab). 
 
N. Statistical analysis 
Results were expressed as the mean ± SEM. The Wilcoxon signed rank test 
and Mann-whitney test were used for analysis of T cell recruitment data and 
relative weight lost. The Log rank test was used for analyzing survival curves. 
Intra-class correlation was used to analyze panniculitis data from paired transfer 
experiments. Student’s t test was used for analysis as indicated in the context. P 
values (2-tailed) less than 0.05 were considered statistically significant. 
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CHAPTER III:  
HETEROLOGOUS IMMUNITY CAN ABROGATE THE 
ROLE OF TNF IN PROTECTION AGAINST VACCINIA 
VIRUS 
TNF is a pivotal cytokine in host defenses and exerts a broad range of effects 
on the innate and adaptive immune systems. It is not surprising that disruption of 
TNF signaling pathways in animal models leads to increased susceptibility to a 
variety of pathogens, such as viruses, bacteria and fungi (Herbein and O'Brien, 
2000; Schluter and Deckert, 2000). Interestingly, clinical trials involving 
TNF-blocking reagents used in a number of autoimmune diseases have generally 
not demonstrated increased susceptibilities to infections which may have been 
predicted. Post-marketing analysis has demonstrated some limited increased 
susceptibility, with sporadically reported cases of infections, particularly by 
Mycobacterium tuberculosis, occurring in patients treated with TNF-blocking 
reagents (Calabrese et al., 2004; Desai and Furst, 2006) 
In mouse studies, experimental viral immunologists go to great lengths to 
assure that their animal colonies are free of endogenous pathogens in order to 
design reproducible experiments. These experimental results are then thought to 
provide the basis for our understanding of the human immune responses to 
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viruses. Although these findings can be enlightening, humans are not 
immunologically naïve, and they often have memory T cell populations which can 
cross-react with and respond to a new related or unrelated infectious agent and 
cause a dramatic difference in disease course, a phenomenon known as 
heterologous immunity. Heterologous immunity can influence protective immunity, 
immunopathology and/or immune deviation of cytokine-producing T cell subsets 
(Welsh and Selin, 2002) and has been well documented in mouse models, as well 
as during human infections (Clute et al., 2005; Urbani et al., 2005; Wedemeyer et 
al., 2001; Welsh et al., 2004). For instance, LCMV-immune mice are partially 
protected against infection with VV, as compared to infected naïve mice (Chen et 
al., 2001; Selin et al., 1998). Cross-reactive LCMV-specific memory T cells are 
activated by VV infection and participate in mediating this protective effect 
(Cornberg et al., 2007; Kim et al., 2005); Cornberg et al., manuscript submitted). 
TNF, a cytokine which is involved in the recruitment and activation of immune 
cells at sites of infection, can act synergistically with IFN-γ to interfere with 
replication of viruses such as VV (Herbein and O'Brien, 2000; Wong et al., 1988). 
Studies using TNFR-/- mice or recombinant VV expressing the TNF gene have 
demonstrated an important role for TNF in controlling the replication of VV in a 
naïve host (Chan et al., 2003; Lidbury et al., 1995; Ruby et al., 1997; Sambhi et al., 
1991).  
By comparing VV loads between TNF-deficient (either neutralizing antibody 
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treatment or genetic KO) and WT VV-infected mice, we directly demonstrated the 
role of TNF in mediating protection against VV in naïve mice. We also attempted 
to understand the requirement for TNF in mediating heterologous immunity in 
LCMV-immune mice, and explain the difference in mouse versus human studies 
concerning the importance of TNF in mediating protection against intracellular 
pathogens. 
 
A. TNF is not required for expansion, recruitment and skewing of 
LCMV-specific CD8 memory T cells at the site of VV infection. 
It has already been demonstrated that LCMV-immune mice have enhanced 
recruitment and activation of cross-reactive LCMV-specific memory CD8 T cells 
into infected peripheral organs, such as the lung after IN inoculation or the 
peritoneal cavity, after IP inoculation of VV (Chen et al., 2001; Kim et al., 2002; 
Selin et al., 1998). We questioned whether the presence of TNF was required for 
this recruitment and activation of cross-reactive LCMV-specific memory T cells. 
We began these studies by examining the accumulation of LCMV-specific CD8 T 
cells at the sites of infection, including the peritoneal cavity and abdominal fat pads, 
after IP infection with VV in LCMV-immune TNF-/- mice. It should be noted that the 
TNF-/- mice generated normal LCMV-specific T cell responses and were able to 
clear LCMV, as shown in previous reports (Klavinskis et al., 1989; Leist and 
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Zinkernagel, 1990). The lymphocytes from the peritoneal cavity and fat pads were 
harvested from both infected and uninfected animals at day 6 of VV infection, 
which is the peak of the VV-specific T cell response and a time point when we 
would expect antigen-specific cells, not bystander memory cells, to accumulate in 
infected peripheral sites (Ely et al., 2003). Due to low cell yields from the peritoneal 
cavity and fat pads, lymphocytes isolated from the same group of five mice were 
pooled. Cells were stimulated with LCMV-specific peptides and examined for IFN-γ 
production by intracellular cytokine staining (ICCS). We calculated the total 
number of LCMV-specific CD8 T cells by combining the total response to five 
well-defined LCMV class-I epitopes (NP396-404, GP33-41, GP276-286, 
NP205-212, GP118-125). In Figure 3.1A, a representative experiment 
demonstrated that the total number of LCMV-specific CD8 T cells increased 9- and 
11-fold in the peritoneal cavity and 117- and 243-fold in the fat pads of the WT and 
TNF-/- LCMV-immune mice, respectively, upon VV challenge. Thus, TNF alone 
does not play a role in mediating expansion and recruitment of cross-reactive 
LCMV-specific CD8 T cells into infected peripheral organs. 
In order to rule out that lymphotoxin (LT), which has redundant functions with 
TNF and uses the same receptors (Aggarwal et al., 1985), could have an effect on 
the recruitment of LCMV-specific CD8 T cells, we utilized the human TNFR II:IgG 
fusion protein, etanercept. Etanercept blocks the activity of both TNF and LT, and it 
is used clinically for the treatment of patients with RA and Crohn’s disease 
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Figure 3.1 TNF and LT were not required for the expansion and
recruitment of LCMV-specific CD8 T cells. WT, TNF-deficient (TNF-/- or
etanercept-treated) and IFNγR-/- LCMV-immune mice were challenged with VV
IP or uninfected. PEC and fat pad lymphocytes were isolated 6 days after VV
infection, and examined by ICCS. Lymphocytes from WT and TNF-deficient
mice were pooled. A shows a representative experiment using TNF-/- mice. B
summaries the results from all the experiments using either TNF-/- mice (solid)
or etanercept-treatment (open). TNF+: WT mice; TNF-: TNF-deficient;
LCMV-imm: LCMV-immune mice; LCMV-imm+VV: LCMV-immune mice infected
with VV. The same symbols represent results from the same experiment.
IFNγR-/- experiments were done separately. Bars represent the mean of each
group. n=5 per group, the Wilcoxon signed rank test was used for statistical
analysis. 
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(Aggarwal, 2003; Feldmann and Maini, 2001). Two days prior to VV infection, 
LCMV-immune WT mice were treated with either 100 μg etanercept or 100 μg IgG 
Fc, as a control. Figure 3.1B, which summarized the results from experiments 
using either etanercept treatment or TNF-/- LCMV-immune mice, demonstrated a 
significant 14-fold (range: 8- to 29-fold) and 9.5-fold (range: 6- to 11-fold) increase 
in LCMV-specific CD8 T cell numbers in the peritoneal cavity of WT and 
TNF-deficient mice respectively, upon VV infection. Although there were more 
variations between experiments, the numbers of LCMV-specific CD8 T cell also 
increased from 0.8- to 163-fold and from 3- to 534-fold in the fat pads of the wild 
type and TNF-deficient LCMV-immune mice respectively, upon VV infection. 
As shown preciously by our group, the protective immunity against VV 
provided by LCMV immunity is abrogated in IFN-γR-/- mice. It was tested whether 
this loss of protection was due to an inability of recruiting LCMV memory cells into 
peripheral organs in the absence of IFN-γ. Like TNF-deficient mice, the 
accumulation of LCMV-specific CD8 T cells was normal in IFNγR-/- mice. 
LCMV-immune IFNγR-/- mice had equivalent numbers of LCMV-specific memory 
CD8 T cells in the peritoneal cavity and fat pads at day 6 after infection with 1X106 
PFU VV IP as control WT mice (Fig 3.1B). 
We have previously reported that each individual LCMV-immune mouse upon 
VV infection selectively expands a different cross-reactive LCMV epitope-specific 
memory CD8 T cell population, leading to different patterns of skewed 
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LCMV-specific responses. This variation in skewing is dependent upon the private 
specificity of the T cell repertoire of each immune mouse (Kim et al., 2005). We 
questioned whether TNF could impact the activation of these cross-reactive 
memory T cell responses by assessing selective expansion of LCMV 
epitope-specific memory T cells. Compared with control mice, the absence of TNF 
did not impact the skewing of LCMV-specific CD8 memory responses during VV 
infection (Fig 3.2 and 3.3). After LCMV immunization, TNF-deficient mice 
developed similar LCMV-specific response as WT mice (Fig 3.2A and 3.3A). The 
two representative WT LCMV-immune control mice demonstrated a preferential 
expansion of LCMV-NP205- or GP33/34-specific T cells (Fig 3.2B). The 
LCMV-immune TNF-/- mice demonstrated similar patterns of skewing, with one 
mouse preferentially expanding both GP33/34- and NP205- specific T cells while 
the other two mice expanded only one of these populations (Fig 3.3B). Different 
patterns of skewing in LCMV-specific response were also evidenced in IFN-γR-/- 
mice. As shown in figure 3.4A, four LCMV-immune mice showed very similar 
hierarchies of LCMV-specific responses. However, after VV infection, the 
hierarchies of LCMV-specific responses were variable between individuals (Fig 
3.4B). Thus, neither TNF/LT nor IFN-γ affects the activation and selective 
expansion of cross-reactive CD8 T cells. 
As shown previously by our group, protection against VV in LCMV-immune 
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Figure 3.2 During VV infection, selective activation and expansion of 
cross-reactive LCMV-specific memory CD8 T cells resulted in skewed 
LCMV response. LCMV-immune C57BL/6J mice were tail bled and 
analyzed for LCMV-specific CD8 T cell responses. Six days post VV 
challenge, splenocytes were isolated and evaluated for the evidence of 
selective expansions of LCMV epitope-specific response during VV 
infection consistent with cross-reactivity. Normal hierarchy of LCMV CD8 T 
cell memory response is shown in A, and VV-induced skewed 
LCMV-specific responses are shown in B. Two representatives of a total of 
twenty VV-infected LCMV-immune mice are shown in B.  
A. LCMV-immune 
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Figure 3.3 TNF was not necessary for the selective activation and 
expansion of cross-reactive LCMV-specific memory CD8 T cells. 
LCMV-immune TNF-/- mice were tail bled and analyzed for LCMV-specific 
memory CD8 T cell response. Six days post VV challenge, lymphocytes were 
isolated from spleens and evaluated for the evidence of selective expansions 
of LCMV epitope-specific CD8 T cell response during VV infection consistent 
with cross-reactivity. Normal hierarchy of LCMV CD8 T cell memory response 
in TNF-/- mice is shown in A, and VV-induced skewed LCMV-specific 
responses are shown in B. Three representatives of twenty VV-infected 
LCMV-immune TNF-/- mice are shown in B.
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B. IFN-γR-/- LCMV+VV 
Figure 3.4 Hierarchies of LCMV-specific CD8 T cell responses in 
IFN-γR-/- mice with or without VV challenge. Figure shows the 
hierarchies of LCMV-specific CD8 T cell responses with or without VV 
challenge in LCMV-immune IFN-γR-/- mice. PEC were harvested from 
uninfected controls (A) and VV day-6 infected mice (B), and then 
examined by ICCS. The responses against these five LCMV epitopes 
were normalized as 100%. The responses from the same mouse were 
linked by lines. 
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mice is mediated by both CD4 and CD8 LCMV-specific memory T cells (Selin et al., 
1998). After TCR-antigen engagement early after VV infection, cross-reactive T 
cells are activated and produce IFN-γ (Chen et al., 2001), a cytokine to which VV is 
very sensitive. Then, activated cross-reactive LCMV-specific T cells migrate to the 
site of infection and mediate more rapid clearance of VV. As shown above, neither 
TNF/LT nor IFN-γ played a role in the activation and accumulation of cross-reactive 
LCMV-specific CD8 T cells into sites of VV replication. However, heterologous 
protective immunity against VV is not evident in either IFNγR-/- mice or in mice 
treated with IFNγ blocking antibody (Selin et al., 1998), indicating an indispensable 
role for IFN-γ in protection against VV in LCMV-immune mice. Additionally, there is 
some evidence suggesting TNF is also required for efficient clearance of VV in 
naïve mice (Lidbury et al., 1995; Ruby et al., 1997; Sambhi et al., 1991). We next 
questioned whether TNF had effects on mediating heterologous protective 
immunity against VV in LCMV-immune mice. 
 
B. In the absence of TNF, prior immunity to LCMV provides 
efficient protection and abrogates the role of TNF during VV 
infection. 
To understand the role TNF plays in controlling VV infection, we first tested 
whether TNF-deficient mice could generate normal VV-specific responses. Figure 
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3.5 shows the experimental protocol, where naïve and LCMV-immune WT and 
TNF-deficient mice were challenged with VV. At day 6 of VV infection, the 
VV-specific response was examined on splenocytes by ICCS. Naïve and 
LCMV-immune etanercept-treated mice generated similar levels of response 
against VV as their IgG-treated controls (Fig 3.6). Similar results were also seen 
in TNF-/- mice after VV challenge (data not shown). 
We next examined whether recruited LCMV-specific memory CD8 T cells 
could mediate protective immunity against VV in TNF-deficient mice. The body 
weight of each individual mouse was recorded daily, after VV infection. As shown 
in Figure 3.7A, non-immune TNF-/- mice lost significantly more weight than WT 
non-immune mice after VV infection, consistent with previous reports (Lidbury et 
al., 1995; Ruby et al., 1997; Sambhi et al., 1991), suggesting that TNF was 
important for controlling VV in naïve mice. Both LCMV-immune WT and TNF-/- 
mice had only minimal weight loss, in contrast to their non-immune controls (Fig 
3.7A), suggesting TNF-/- LCMV-immune mice also had protective immunity against 
VV. To more directly demonstrate whether TNF was required for mediating the 
heterologous protective immunity against VV, the VV titers of the fat pads and 
testes at day 6 post VV infection were determined by plaque assay. Viral loads 
were significantly decreased in TNF-/- LCMV-immune mice compared to naïve 
TNF-/- controls (Fig. 3.8A; Table 3.1), indicating that the heterologous protective 
immunity against VV provided by LCMV immunity was not dependent on TNF. Our 
data directly showed that there was a significant 11-fold increase in VV titers in 
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B. Experiment with TNF blockade
Figure 3.5 Experimental design to test the role of TNF and LT in 
mediating heterologous protective immunity against VV. 
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Figure 3.6 TNF-deficient mice had comparable levels of 
VV-specific response as WT controls. Naïve and LCMV-immune 
IgG or Etanercept treated mice were infected with VV. At day 6 of 
infection, splenocytes were harvested and stimulated with VV-infected 
DC2.4 for 5 hours, and then stained for CD8, CD44 and intracellular 
IFN-γ production. Cells were gated on CD8+ lymphocytes. One 
representative mouse from each group is shown. 
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Figure 3.7 Immunity to LCMV protected TNF-deficient mice from losing
weight during VV infection. WT or TNF-/- LCMV-immune mice and age
matched naïve controls (A); IgG- or etanercept-treated LCMV-immune mice
and age matched naïve controls (B) were challenged with VV. Relative
weights are shown. n=4 or 5 per group; A Mann-whitney test was used for
statistical analysis, **, p < 0.01. Graphs show the averages of each group
±SEM. A shows a representative of four experiments with similar results; B
shows a representative of three experiments with similar results. 
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Figure 3.8 Previous immunity to LCMV compensated for the 
absence of TNF and LT in protection against VV infection. WT or 
TNF-/- LCMV-immune mice and age matched naïve controls (A), IgG or 
etanercept-treated LCMV-immune mice and age matched naïve controls 
(B) were challenged with VV. Viral titers in fat pads and testes were 
determined 6 days post VV infection by plaque assay. n=4 or 5 per group;
student’s t test was used for statistical analysis, P value is indicated, if 
p>0.05; *, p ≤ 0.05; **, p < 0.01, ***, p < 0.001. Graphs show the 
averages of each group and the error bars represent ±SEM. A shows a 
representative of four experiments with similar results; B shows a 
representative of three experiments with similar results. 
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Table 3.1 Immunity to LCMV decreased VV titers in the absence of TNF and LT 
Mean (±SEM) Log10 of VV titer in the Fat Pad 
Exp 
TNF+ 
Naïve 
+VV 
TNF+ 
LCMV- 
imm+VV 
% of 
inhibition 
TNF- 
Naïve 
+VV† 
TNF- 
LCMV 
-imm+VV¶ 
% of 
inhibition
1 3.8±0.5 2.2±0.3 97.5 4.9±0.1 (+1.1) 1.6±0.6 (-0.6) 99.9 
2 4.2±0.4 3.5±0.3 80.0 3.9±0.5 (-0.3) 2.5±0.7 (-1.0) 96.0
3 4.3±0.3 1.3±0.3 99.9 5.4±0.2 (+0.9) 1.9±0.7 (+0.6) 100.0 
4 4.4±0.7 1.6±0.4 99.8 4.1±0.2 (-0.3) 1.9±0.5 (+0.3) 99.4 
5 2.5±0.4 2.1±0.6 60.2 3.2±0.4 (+0.7) 2.7±0.8 (+0.6) 68.4 
6 2.3±0.4 UND 95.0 3.3±0.5 (+1.0) 1.2±0.2 (+0.2) 99.2 
7 2.4±0.4 1.9±0.6 68.4 3.9±0.2 (+1.5) 3.0±0.5 (+1.1) 87.4 
Mean of 
means 
3.4±0.3 2.1±0.3# 85.5±5.8 4.1±0.3# (+0.7) 2.3±0.3
§‡ 
(+0.2) 
92.9±4.
 
Mean (±SEM) Log10 of VV titer in the Testis 
Exp 
TNF+ 
Naïve 
+VV 
TNF+ 
LCMV- 
imm+VV 
% of 
inhibition 
TNF- 
Naïve  
+VV† 
TNF- 
LCMV 
-imm+VV¶ 
% of 
inhibiti
 
1
on
1 3.5±0.3 1.9±0.4 97.5 4.6±0.1 (+1.1) 1.6±0.4 (-0.3) 99.9 
2 2.8±0.5 1.7±0.3 92.1 1.8±0.6 (-1.0) 1.3±0.3 (-0.4) 68.4
3 2.6±0.3 1.3±0.2 95.0 3.9±0.2 (+1.3) 1.6±0.4 (+0.3) 99.5 
4 1.4±0.4 UND 96.0 3.0±0.2 (+1.6) UND 99.0
5 3.4±0.3 1.4±0.3 99.0 3.8±0.4 (+0.4) 3.0±0.5 (+1.6) 84.2 
6 2.0±0.6 1.2±0.2 84.2 3.5±0.3 (+1.5) 1.4±0.2 (+0.2) 99.2 
7 2.6±0.4 2.4±0.6 36.9 3.5±0.3 (+0.9) 2.6±0.4 (+0.2) 87.4 
Mean of 
means 
2.6±0.2 1.8±0.3# 85.8±7.8 3.5±0.3# (+0.8) 1.9±0.3
§‡ 
(+0.3) 
91.1±4.
Fat pads and testes were titrated at day 6 of VV infection. VV titers differed
between experiments due to the use of different viral stocks (n=4 or 5 mice/group)
Numbers in parentheses represent the log change compared to †TNF+ naïve+VV
or ¶ TNF+ LCMV-imm+VV mice. Statistically significantly different from #TNF+
naïve+VV mice (Student’s paired t test, p<0.05). or §TNF- naïve+VV mice 
(p<0.01). ‡ No significant difference between TNF+ and TNF- LCMV+VV mice
(Student paired t test, p=0.5 for FP and p=0.4 for testes). UND, undetectable. 
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TNF-/- non-immune mice in comparison to non-immune WT mice (Fig. 3.8A; Table 
3.1). In contrast, the TNF-/- LCMV-immune mice controlled VV replication as 
efficiently as WT LCMV-immune mice, suggesting that the prior immunity to LCMV 
made TNF less important in protection against VV infection (Fig. 3.8A; Table 3.1).  
To rule out the possibility of LT compensating for the lack of TNF, we used 
etanercept treatment to block both TNF and LT function. These studies 
recapitulated the findings in the TNF-/- mice. Etanercept-treated LCMV-immune 
mice were comparable to WT LCMV-immune mice showing significantly less 
weight loss, and more rapid virus clearance upon VV infection (Fig. 3.7B; 3.8B and 
Table 3.1) than IgG-treated or etanercept-treated naïve controls. 
The efficient clearance of VV in LCMV-immune mice was observed in all the 
experiments using TNF-/- mice or etanercept treatment, with WT and TNF-deficient 
(TNF-/- and etanercept-treated) LCMV-immune mice showing an average of 85% 
and 91-92% lower VV titers in fat pads and testes than their naïve controls, 
respectively (table 3.1). While, the VV loads in TNF-deficient naïve mice were 
almost a log higher than those in WT naïve mice, after VV infection. These data 
indicate that TNF played a role in protection against VV in naïve mice, but neither 
TNF nor LT was needed for mediating heterologous protective immunity against 
VV in LCMV-immune mice. In fact, the prior immunity to LCMV can abrogate the 
role TNF plays in defending against VV in naïve mice. 
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C. Prior immunity to LCMV protects TNF-deficient mice from 
lethal VV infection. 
According to the data shown above, it seemed that TNF/LT was not important 
for mediating heterologous protective immunity against VV. We then tested 
whether LCMV-immunity itself would be enough to protect against lethal VV 
infection in the absence of TNF signaling.  Previous studies have shown that the 
protective immunity mediated by LCMV memory T cells protect mice from a lethal 
VV challenge in the respiratory infection model (Chen et al., 2001). Here we 
demonstrated for the first time that LCMV-immune mice were also protected 
against a lethal IP VV challenge (Fig 3.9A). After a lethal dose VV infection, the 
LCMV immunity significantly (p=0.03) increased the time of median survival from 
5 days in non-immune mice to 9.5 days in immune mice. To test whether immunity 
to LCMV could protect the host from a lethal VV infection in the absence of TNF, 
LCMV-immune TNF-/- or etanercept-treated WT mice were infected with lethal 
doses of VV IP. Dramatic protection was found in etanercept-treated mice. After 
infection with a lethal dose (4X106 PFU) of VV IP, all the etanercept-treated naïve 
mice were dead by day 7, while 50% of the etanercept-treated LCMV-immune 
mice survived the infection (Fig 3.9B). Figure 3.9C shows the survival of naïve and 
LCMV-immune TNF-/- mice after infection with 1.6X106 PFU VV IP. The mortality 
was decreased significantly from 80% in the naïve TNF-/- mice, to 45% in the 
immune TNF-/- mice. We were also able to demonstrate similar results in the IN 
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Figure 3.9 LCMV-immune mice were protected against lethal VV IP
infections in the absence of TNF and LT. LCMV-immune mice (open 
circle) and naïve controls (solid circle) were infected with lethal dose of VV
IP. The percentage of survival was recorded daily till the end of 
experiment. A, naïve (n=9) and LCMV-immune (n=10) WT mice were 
infected with 5.0 X 106 PFU of VV. B, naïve (n=10) and LCMV-immune 
(n=10) etanercept-treated WT mice were infected with 4.0X106 PFU of VV. 
C, naïve (n=10) and LCMV-immune (n=11) TNF-/- mice were infected with 
1.6X106 PFU VV. The Log rank test was used for statistical analysis; *, p < 
0.05; ***, p < 0.001. 
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model of infection with VV in LCMV-immune mice. There was significantly less 
mortality upon lethal VV infection in both IgG- or etanercept-treated 
LCMV-immune mice (20% and 10% respectively) than the control IgG- or 
etanercept-treated non-immune mice (70% and 50% respectively) (Fig 3.10). Thus, 
prior immunity to LCMV could protect a host from a lethal infection with VV even in 
the absence of TNF, a cytokine important in mediating protection against VV in 
naïve mice. 
D. Chapter summary 
By using TNF-/- mice, we directly confirm the importance of TNF in defending 
against VV in naïve mice; however, prior immunity to a virus such as LCMV 
completely alters the picture. A LCMV-immune TNF-deficient host has a 
comparable level of protection to VV as a WT LCMV-immune host, suggesting that 
TNF and LT do not mediate heterologous protective immunity against VV in 
LCMV-immune mice. The heterologous immunity found in these mice, most likely 
through IFN-γ production by cross-reactive memory CD8 T cells, can completely 
substitute for the antiviral effect of TNF and LT in protection against VV in naïve 
mice. These data imply that the anti-TNF therapies to treat various painful 
diseases in humans may be relatively safe perhaps in large part due to 
heterologous immunity. Since humans have been exposed to many pathogens 
throughout their lives, they have a large complex pool of memory T cells that have 
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Figure 3.10 Immunity to LCMV significantly reduced the mortality of 
hosts challenged with lethal dose VV IN. IgG- (A) or etanercept-treated 
(B) LCMV-immune mice (open circle) and naïve controls (solid circle) were
infected with 4.0 X 104 PFU of VV IN. The percentage of survival was 
recorded daily till the end of experiment. The Log rank test was used for 
statistical analysis; n=10 per group; *, p < 0.05. 
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the potential to cross-react with any new pathogen and mediate heterologous 
protective immunity. 
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CHAPTER IV: 
PATHOLOGICAL FEATURES OF HETEROLOGOUS 
IMMUNITY ARE REGULATED BY THE PRIVATE 
SPECIFICITIES OF THE IMMUNE REPERTOIRE 
A number of studies have shown that the T cell response to viral infections 
may be influenced by memory T cells generated in response to unrelated 
pathogens (Brehm et al., 2002; Chen et al., 2001; Clute et al., 2005; Selin et al., 
1998; Urbani et al., 2005). This alteration in responses is displayed by changes in 
T cell immunodominance hierarchies (Brehm et al., 2002; Kim et al., 2005), by 
alterations in viral loads and protective immunity, and by marked changes in 
immunopathology (Chen et al., 2001; Selin et al., 1998). This ‘heterologous 
immunity’ can be a consequence of unanticipated T cell cross-reactivity between 
different pathogens. Indeed, T cell specificity can be quite degenerate, and 
cross-reactivity between different viruses is common. For example, human studies 
have revealed strong T cell cross-reactivity between influenza A virus (IAV) and 
Epstein-Barr virus (EBV) epitopes (Clute et al., 2005). In some patients, a subset 
of HLA-A2-restricted EBV-BMLF1 specific T cells is cross-reactive to IAV-M1. A 
cross-reactive response is also identified between IAV and hepatitis C virus (HCV) 
epitopes (Urbani et al., 2005). The T cells that are specific to HCV-NS3 epitope can 
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cross-react with IAV-NA. 
A property of heterologous immunity noted both in the humans and mice is 
that there can be dramatic variation in pathogenesis and in the cross-reactive 
specificities of the T cell responses between individuals. Mouse studies have 
shown that such variation can even occur in genetically identical individuals 
subjected to similar infection histories. In genetically identical LCMV-immune mice 
challenged with VV, T cell immunodominance and cross-reactivity patterns varied 
among mice, such that, for example, in some mice VV selectively expanded CD8 T 
cells cross-reactive with LCMV epitope NP205-212, whereas in other mice there is 
selective expansion of CD8 T cells specific to GP34-41 or to GP118-125 (Kim et al., 
2005). Additionally, T cell adoptive transfer studies indicated that individual 
LCMV-immune mice had unique patterns of CD8 T cell cross-reactivity to VV, and 
that the private specificities of the T cell repertoires in individuals regulated the 
magnitude and the specificities of T cell responses under conditions of 
heterologous immunity (Kim et al., 2005).  
Human diseases involving suspected heterologous immunity, such as 
EBV-induced acute mononucleosis, HCV-induced hepatitis, and even dengue 
virus-induced hemorrhagic fever and shock syndrome all present with marked 
variations in immunopathology between individuals. In this chapter, we tested the 
hypothesis that variations in immunopathology under conditions of heterologous 
immunity were, like the specificity of the T cell response, also regulated by the 
private specificity of the immune repertoire. To do so, we used the mouse model of 
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heterologous immunity between LCMV and VV.  
Naïve C57BL/6 male mice infected IP with 1X106 PFU of VV, strain WR, 
usually show little or no pathology in visceral fat pads 6 days post infection, while 
LCMV-immune mice, on infection with VV, develop panniculitis, in the form of 
acute fatty necrosis (Selin et al., 1998). The levels of panniculitis in LCMV-immune 
mice were scored at day 6 of VV infection. The variation in levels of panniculitis in 
LCMV-immune mice ranges from none to very severe levels, as shown in figure 
4.1. By using adoptive transfers of splenocytes from LCMV-immune mice into 
naïve hosts subsequently challenged with VV Fig 1.5, we examined whether the 
individual differences in pathogenesis of panniculitis were determined by the 
private specificity of the immune host. 
 
A. Splenocytes from a single LCMV-immune donor show similar 
expansions of LCMV-specific CD8 T cell response in 
adoptively transferred recipients. 
The visceral fat pads that are subject to panniculitis in this model line the 
peritoneal cavity. To first determine if the response of T cells isolated from infected 
peripheral tissue is a function of the private specificity of the immune repertoire, as 
we have shown in the spleen, CFSE-labeled LCMV-immune splenocytes derived 
from a single donor mouse were transferred into two naïve Ly5.2 congenic 
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Figure 4.1 Different levels of panniculitis developed in
LCMV-immune mice during VV infection. LCMV-immune mice were 
challenged with 1X 106 PFU VV IP. The levels of panniculitis were 
record at day 6 of VV infection.  
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recipients. At day 6 of VV infection, the donor peritoneal exudate cell (PEC) 
responses against LCMV epitopes (NP396-404, GP33-41, GP276-286, NP205-212 and 
GP118-125) were examined. As shown in figure 4.2, both recipients receiving donor 
cells from LCMV-immune donor 1 and 3 selectively expanded GP33- and 
NP205-specific T cells. On the other hand, very little proliferation was observed in 
GP33-specific CD8 T cells from both recipients receiving cells from LCMV-immune 
donor 2. Expansions of GP276-specific CD8 T cells were seen in both recipients 
receiving donor cells from LCMV-immune donor 4. This experiment confirms that 
the specificity of the memory LCMV-specific T cell response elicited by VV in the 
periphery is a function of the immune repertoire of the individual immune host. 
 
B. The private specificity of LCMV-immune T cell repertoire 
determines the levels of immunopathology induced by VV 
infection. 
We have shown previously that the panniculitis in this model of heterologous 
immunity is mediated by T cells (Selin et al., 1998). Transfers of splenocytes from 
LCMV-immune mice into naïve mice prior to VV infection could elicit this pathology. 
Variation in pathology is dramatic among LCMV-immune mice after VV infection 
(Fig. 4.1), so we tested here whether such variation in pathology could be linked to 
the private immune repertoire. After transfer of LCMV-immune splenocytes 
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Figure 4.2 Recipients received splenocytes derived from a single 
LCMV-immune donor showed similar skewing in LCMV-specific CD8 T cell 
response after VV challenge. At day 6 of VV infection, LCMV-specific responses 
of donor cells isolated from PEC were examined by ICCS. Cell division of gated 
donor CD8 T cells was shown by loss of CFSE, and the specificity of the response 
was examined by intracellular IFN-γ assay. 
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derived from a single donor into two naïve recipients, both recipients were 
challenged with VV. The levels of panniculitis at day 6 of VV infection were 
recorded. Figure 4.3 shows fat pad pathology from two sets of donor-recipient 
pairs. The two recipients receiving memory cells from immune donor 1 both 
showed none or very mild panniculitis, while the fat pads isolated from recipients 
transferred with cells from donor 2 both showed considerably higher levels of 
panniculitis. This type of experiment was done four times with 4-5 donors per 
experiment, and the results are shown in Table 4.1. The two recipients from a given 
donor had very similar levels of panniculitis after VV challenge. With three 
exceptions, all paired donor recipients had either identical pathology scores or else 
pathology scores ± one unit on an eight unit scale (Table 4.1). Two of the 
exceptions were just two units different. In contrast, the levels of panniculitis in 
recipients receiving memory cell populations from different LCMV-immune donors 
varied dramatically and ranged from zero to six (Table 4.1). To compare whether 
the variation within paired recipients was statistically significantly less than the 
variation between unpaired recipients, we used intra-class correlation to analyze 
our data. We found that the two observations of each pair fell into a moderate 
correlation (r2=0.6, p=0.002, Table 4.1). These data indicate that the pathogenesis 
of panniculitis in LCMV-immune mice during VV infection is also predetermined by 
the private specificity of the T cell repertoire. One exception was found in 
experiment 2. In the second pair, host 1 showed mildly moderate level (3) of 
panniculitis, while the other host had severe (6) panniculitis, which suggested that 
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Figure 4.3 Recipients received splenocytes derived from a single 
LCMV-immune donor exhibited similar levels of VV-induced 
panniculitis. Two recipients transferred with splenocytes derived from a 
single LCMV-immune donor were infected with VV one day post transfer. 
At day 6 of infection, the levels of panniculitis were recorded. 
Representative pictures of two sets of donor-recipients pairs are shown.
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Table 4.1 Two hosts receiving splenocytes from one LCMV-immune donor
developed similar levels of panniculitis.  
 
Experiment  Host 1* Host 2* 
 
Exp I 
2 3 
1 3 
4 4 
4 3 
1 2 
Exp II 
2 1 
3 6 
3 2 
3 3 
Exp III 
1 0 
3 2 
1 3 
2 1 
1 2 
Exp IV 
0 1 
0 0 
3 4 
1 0 
2 2 
ICC# 0.6 
P value 0.002 
 
 
* Hosts 1 and 2 on the same row represent the two mice transferred with
splenocytes derived from a single LCMV-immune donor. 
# ICC, intra-class correlation. 
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there might be another uncontrolled factor affecting the levels of panniculitis. 
 
C. Pooled splenocytes from multiple LCMV-immune donors 
result in similar patterns of heterologous T cell responses and 
levels of immunopathology in all recipients. 
As shown above, similarities in skewing of LCMV-specific CD8 T cell 
responses and development of panniculitis were observed in paired VV-infected 
recipients receiving LCMV-memory cells from single donors. We next tested 
whether pathology scores would be similar in multiple recipients that are 
transferred of mixed splenocytes from several LCMV-immune mice. Pooled 
splenocytes from multiple donors were transferred into four or five naïve recipients. 
At day 6 of VV infection, the LCMV-specific CD8 T cell responses were examined 
and the levels of panniculitis were recorded. In experiment I, all four recipients 
receiving pooled LCMV-immune splenocytes generated similar T cell responses, 
as shown in figure 4.4, where all recipients expanded the NP205-specific T cell 
population. This result is consistent with the data in figure 4.2, which shows that 
recipients receiving same donor populations generate similar patterns of skewing 
of LCMV-specific responses. 
Then, we compared the levels of panniculitis that developed in these 
recipients. We found that most of the recipients developed similar levels of 
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Figure 4.4 Most of the recipients receiving a same pool of splenocytes from 
multiple LCMV-immune donors showed similar skewing in LCMV-specific 
CD8 T cell repertoire. Pooled LCMV-immune splenocytes derived from multiple 
LCMV-immune donors were transferred into four or five naïve mice, which then
were infected with VV. The splenocytes were isolated and examined at day 6 of 
infection. The pre- and post transfer responses of donor cells are shown.
Percentages of epitope-responding CD8 T cells are shown in the top right
quadrant. After subtracting the background, the fold increase of the percentage of 
epitope-specific CD8 T cells during VV infection are indicated in parentheses on
the top of the plot. Three independent experiments showed similar results. 
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panniculitis (Fig 4.5). However, in every experiment, there was one mouse that 
behaved quite differently from the rest of the recipients. For instance, in 
experiment 1, one mouse developed a moderately severe level (5) of panniculitis, 
while others were at very mild level (1). Therefore, our data demonstrated that 
private specificity of the memory pool played a main effect on determine 
pathogenesis of panniculitis in LCMV-immune mice during VV infection, though 
other unknown factors may also be involved. 
 
D. Chapter summary 
By using the adoptive transfer technique, for the first time we directly confirm 
the importance of the private specificity of memory T cell repertoires in determining 
the pathogenesis of immunopathology during heterologous viral infection. 
Splenocytes derived from a single LCMV-immune donor induced similar levels of 
panniculitis in two recipients, while cells from different immune donors induced 
variations in the levels of panniculitis among recipients. Thus, the levels of 
panniculitis are determined by the unique features of the memory T cell repertoires. 
Similar scores of pathology and skewing of the hierarchies of LCMV-specific CD8 
T cells were also observed in multiple recipients adoptively transferred with pooled 
LCMV-immune splenocytes from multiple donors. Taken together, our study 
indicates that the private specificity is the main contributor in the variations in the 
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Figure 4.5 Most of the recipients receiving a same pool of
splenocytes from multiple LCMV-immune donors showed similar
levels of panniculitis. Pooled splenocytes derived from multiple
LCMV-immune donors were transferred into four or five naïve mice,
which then were infected with VV. At day 6 of infection, the levels of
panniculitis were recorded. Graph shows the levels of panniculitis
from three independent experiments. 
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pathogenesis of immunopathology observed in genetically identical individuals 
during heterologous viral infection. 
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CHAPTER V: 
TNF/LT AND FASL MEDIATE THE PATHOGENESIS OF 
PANNICULITIS IN LCMV-IMMUNE MICE DURING VV 
INFECTION 
Panniculitis is a group of diseases that involve inflammation of adipose tissue. 
It is histologically characterized by the infiltration of inflammatory cells and 
necrosis of fat cells (Requena and Yus, 2001). Erythema nodosum (EN) is the 
most common form of panniculitis (Requena and Yus, 2008). It presents with 
painful, tender, erythematous subcutaneous nodules usually 1-5 cm in diameter, 
and is most commonly located on the anterior portion of the lower legs, arms and 
soles. The etiology of EN is unknown, but is associated with fungal diseases, 
infectious mononucleosis, intracellular bacterial and viral infections (Requena and 
Yus, 2008). It has been reported that EN can occur after vaccination, including with 
VV for smallpox (Gaertner et al., 2004). Panniculitis may also occur in visceral fat 
tissue and be extremely debilitating in association with lupus, scleroderma, 
lymphomas and pancreatitis (Requena and Yus, 2001).  Several groups have 
reported that the utilization of drugs to block the function of TNF improves EN 
when it presents with autoimmune diseases, such as Crohn’s disease, sarcoldosis 
or as erythema nodosum leprosum during leprosy (Haley et al., 2004; Kugathasan 
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et al., 2003; Roberts et al., 2003; Sheskin, 1980). This is highly suggesting that 
TNF may be involved in the pathogenesis of EN and other forms of panniculitis.  
TNF modulates the immune system at a variety of levels, including 
inflammation, cell trafficking, activation, differentiation, proliferation, death and 
development of lymphoid tissue (De et al., 1994; Kim and Teh, 2004; Pasparakis et 
al., 1997; Singh and Suresh, 2007; Vassalli, 1992; Yu et al., 2003). TNF has a key 
role in mediating host defense against pathogens including VV, as we have 
discussed previously (see introduction and Chapter III). Both TNFR1 and TNFR2 
have been shown to be required for mediating protection against VV (Chan et al., 
2003; Ruby et al., 1997). The protection may be mediated at least partially by 
killing of the VV infected cells by necrosis. It has been shown that during VV 
infection, when caspase-8 is inhibited by the viral inhibitor SPI-2 (Shisler and Moss, 
2001), signaling through TNFR1 can trigger programmed necrotic death (Holler et 
al., 2000). It has also been shown that TNFR2 is required to enhance the 
TNFR1-induced programmed necrosis (Chan et al., 2003). Similar to TNF, FasL 
and TRAIL, other members of TNF superfamily, can also induce programmed 
necrosis (Holler et al., 2000). Fas-FasL interactions have been suggested to be 
involved in some types of autoimmune diseases (Li et al., 2004), as well as fat 
pathology (Fischer-Posovszky et al., 2006). Fischer-Posovszky et al. found that in 
patients with acquired lipodystrophy, adipose tissue sections from the regions with 
ongoing fat loss were positive for Fas. They also found that the co-treatment of 
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IFN-γ and TNF could sensitize human adipocytes to Fas-mediated apoptosis in 
vitro. Since the histological analysis of panniculitis shows fat cell necrosis, we 
hypothesized that TNF, FasL and TRAIL were involved in mediating the enhanced 
panniculitis in LCMV-immune mice during VV infection. To test our hypothesis, we 
compared the levels of panniculitis in VV-infected LCMV-immune mice in the 
presence or absence of TNF, FasL and TRAIL by using either blocking antibodies 
or genetically deficient mice. This thesis demonstrates that TNF, LT and FasL all 
participate in enhancing panniculitis in VV infected LCMV-immune mice, but that 
TRAIL only plays a minor role in this process.  
 
A. TNF and LT are involved in enhancing panniculitis in 
LCMV-immune mice during acute VV infection. 
Prior immunity to LCMV can induce immunopathology manifested by 
extensive panniculitis, in the form of acute fatty necrosis in visceral fat pads 4-7 
days post VV challenge (Selin et al., 1998; Yang et al., 1985). As shown in Figure 
1.6A, LCMV-immune mice develop severe and moderate levels of panniculitis on 
the visceral fat pads after infection with 1.0X106 PFU VV IP. In contrast, most of the 
non-immune mice after infection with VV showed only very mild levels of 
panniculitis (Fig 1.6A).  
As discussed earlier, TNF is a very important inflammatory cytokine, required 
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for controlling the clearance of variety of pathogens, such as viruses, bacteria and 
fungi (Schluter and Deckert, 2000). However, It has also been suggested to be 
involved in tissue damage and human autoimmune diseases (Bolger and Anker, 
2000; Moore et al., 1999; Uysal et al., 1997). Thus, we first tested whether the 
VV-induced panniculitis in LCMV-immune mice was due to the function of TNF and 
LT by using etanercept to block the activities of both TNF and LT. Two days prior to 
VV infection, LCMV-immune or naïve C57BL/6 mice were treated with either 
100μg etanercept or 100μg control human IgG-Fc. All the mice were infected with 
1X106 PFU of VV IP. As shown in Fig 5.1A, TNF blockade significantly (p=0.0004) 
abrogated the enhancement of panniculitis in LCMV-immune mice. At day 6 of VV 
infection, the LCMV-immune mice that received IgG treatment showed 
significantly increased panniculitis, as compared to IgG treated naïve mice 
(p=0.0009). Etanercept treatment efficiently decreased the severity of panniculitis 
in VV-infected LCMV-immune mice to a similar basal level as seen in TNF blocked 
naïve mice (p=0.2). The difference in the development of panniculitis between IgG 
and etanercept treated LCMV-immune mice after VV infection was not due to 
different rates of viral clearance, as they had similar viral titers in their fat pads and 
testes at day 6 of VV infection (Chapter III, Fig 3.8).  
Private specificity of cross-reactive LCMV memory population induces 
tremendous variation in the level of acute panniculitis during VV infection as 
described in the Chapter IV. In order to control for the variable and directly test 
whether TNF and LT were important for mediating panniculitis induced by 
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Figure 5.1 Blocking of TNF and LT completely abrogated the increase of 
VV-induced panniculitis in LCMV-immune mice. A, etanercept (etan)- or 
IgG-treated naïve and LCMV-immune mice were infected with 1X106 PFU VV IP. 
The levels of panniculitis were recorded at day 6 of infection. B, One pool of
LCMV memory splenocytes derived from multiple donors were transferred into 9 
or 10 naïve mice. Half of the recipients were treated with etanercept, and the 
other half received IgG treatment as control. Levels of panniculitis were recorded 
at day 6 of infection. Pooled results from two independent experiments are 
shown. (exp I (solid) and exp II (open)). Student’s t test was used for statistical 
analysis. 
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cross-reactive LCMV memory cells upon VV infection, we adoptively transferred 
the same pool of lymphocytes from multiple LCMV-immune donors into a group of 
WT naïve C57BL/6J mice. Half of these mice then received etanercept treatment, 
and the rest were treated with IgG as control. The etanercept-treated mice showed 
significantly lower levels of LCMV-memory cell-induced panniculitis than 
IgG-treated controls (Fig 5.1B), further suggesting the role of TNF and LT in 
mediating panniculitis induced by LCMV immunity during acute VV infection. 
The fat pads were extracted from IgG- and etanercept-treated VV infected 
LCMV-immune mice. Examples from both groups are shown in figure 5.2A. The 
fat pad extracted from the IgG-treated group showed moderate level of 
panniculitis, while the fat pad from the etanercept-treated mouse had none. 
Paraffin-embedded fat pads were sectioned at 5μm and stained with hematoxylin 
and eosin (H&E). As shown in figure 5.2B, the fat pad extracted from IgG-treated 
mice showed dramatic necrosis of fat cells, and massive infiltration of 
mononuclear cells into the fat tissue. In contrast, the fat pad isolated from 
etanercept-treated mice had normal fat tissue structure and showed only mild 
infiltration of mononuclear cells. Since the LCMV-specific memory CD8 T cells 
could still be recruited into the fat pads in the etanercept-treated mice (as seen in 
Chapter III, Fig 3.1), the absence of panniculitis in these mice was not due to the 
failure of recruitment of LCMV-specific T cells.  
To further dissect the role of TNF versus LT on the development of panniculitis, 
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Figure 5.2 Anti-TNF treated LCMV-immune mice showed little panniculitis 
and normal fat tissue structure. Etanercept- or IgG-treated LCMV-immune 
mice were infected with VV. Day 6 of infection, visceral fat pads were isolated.
Representative pictures of fat pads are shown in A. B, fat pad sections from IgG 
treated (a-c) and etanercept-treated (d) LCMV-immune mice infected with VV fo
LCMV+IgG+VV LCMV+etanercept+VV
A 
B a 
c 
b
10X 20X
20X 
d
20X
r 
6 days were stained with H&E. (a) Fat pad with moderately sever panniculitis
isolated from IgG-treated LCMV-immune mice at day 6 of VV infection showed
(b) massive infiltration of lymphocytes (pointed by the arrows) and (c) extensive 
necrosis of fat cells. (d) Fat pad with no panniculitis from VV-infected 
etanercept-treated LCMV-immune mice showed normal architecture. 
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we compared the induction of panniculitis between TNF-/- and WT LCMV-immune 
mice. It has been shown that TNF is not required for establishing normal immune 
responses against LCMV infection and LCMV clearance (Calzascia et al., 2007; 
Klavinskis et al., 1989; Leist and Zinkernagel, 1990; Suresh et al., 2005), so we 
were able to utilize LCMV immunized TNF-/- mice for our studies. Since naive 
TNF-/- mice were more susceptible to VV infection (Chapter III), LCMV-immune WT 
and TNF-/- mice together with their naïve controls were infected with 7.5X105 PFU 
VV IP. The levels of panniculitis were recorded at day 6 of infection. Consistent 
with the results from the blocking studies, at day 6 of VV infection the levels of 
panniculitis were significantly increased in WT LCMV-immune mice, as compared 
to their naïve controls (p=0.02) (Fig 5.3). TNF-/- LCMV-immune mice showed only a 
slight increase in the levels of panniculitis compared to TNF-/- non-immune mice 
(p=0.3). However, when we compared TNF-/- LCMV-immune mice to WT immune 
mice, we did not find a significant decrease in the levels of panniculitis (p=0.4). 
These results suggest that TNF may only play a partial role in mediating 
panniculitis, and that TNF may work together with LT to fully induce the 
development of panniculitis in LCMV-immune mice during VV infection. 
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Figure 5.3 TNF alone only played a partial role in mediating 
panniculitis in LCMV-immune mice during VV infection. LCMV 
immunized C57BL/6J or TNF-/- mice and their naïve controls were 
infected with 7.5X105 PFU VV IP. At day 6 post infection, significantly 
increased levels of panniculitis were found in LCMV-immune C57BL/6J 
mice, but the enhancement of panniculitis was slightly decreased in 
TNF-/- LCMV-immune mice, as compared to their controls. n=20 per
group, error bars represent ±SEM, Student’s t test was used for 
statistical analysis. 
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B. FasL is required to mediate the pathogenesis of 
panniculitis in VV-infected LCMV-immune mice.  
FasL, another member of TNF superfamily, can also induce apoptosis and 
programmed necrosis upon engagement with its receptor, Fas (Holler et al., 2000). 
It has also been shown to be involved with adipocyte apoptosis in patients with 
lipodystrophy, a syndrome with partial or complete loss of adipose tissue 
(Fischer-Posovszky et al., 2006). To test whether FasL was also involved in the 
pathogenesis of panniculitis in our model, we challenged naïve and 
LCMV-immune gld (FasL-deficient) as well as WT mice with 1.0X106 PFU VV IP. 
As shown in figure 5.4A, both naïve gld mice and LCMV-immune gld mice 
developed very little panniculitis. LCMV-immune gld mice did not show increased 
levels of immunopathology after VV infection, compared to gld non-immune mice 
(p=0.7) (Fig 5.4A). The deficiency in FasL decreased the levels of panniculitis in 
LCMV-immune mice remarkably (p<0.0001). The absence of panniculitis in 
VV-infected gld LCMV-immune mice was not due to the failure of recruiting 
LCMV-specific T cells into infected peripheral tissues. As shown in figure 5.4B, 
more LCMV-specific CD8 T cells were detected in peritoneal cavity and fat pad in 
gld mice than in WT mice at day 6 of VV infection. Representative fat pads and 
histology slides of non-infected mice and VV-infected LCMV-immune WT and gld 
mice are shown in figure 5.5. The fat pad extracted from a naïve mouse showed 
healthy intact fat tissue structure (Fig 5.5A). After heterologous VV challenge, the 
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Figure 5.4 FasL-deficiency abrogated VV-induced panniculitis in 
LCMV-immune mice completely. LCMV-immune C57BL/6J or FasL-deficient 
(Gld) mice and their naïve controls were infected with 1X106 PFU VV IP. At day 
6 of infection, the levels of panniculitis were recorded (A) and pooled 
lymphocytes isolated from PEC and fat pads were examined by ICCS (B). B
shows a representative out of three independent experiments. Student’s t test 
was used for statistical analysis. 
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fat pads isolated from WT LCMV-immune mice showed moderately severe levels 
of panniculitis and massive fat cell necrosis and lymphocyte infiltration (Fig 5.5B). 
However, most VV-infected gld LCMV-immune mice had no panniculitis (Fig 5.4A), 
although they still showed large amounts of mononuclear cell infiltrates (Fig 5.5C) 
and LCMV-specific CD8 T cells into their fat tissue (Fig 5.4B). Thus, FasL is 
required for the development of panniculitis in LCMV-immune mice during VV 
infection. 
Finally, we tested the role of TRAIL in mediating panniculitis in LCMV-immune 
mice during VV infection. TRAIL, like TNF and FasL, is also a member of the TNF 
superfamily. It is important for regulating immune responses and eliminating tumor 
cells (Aggarwal, 2003). Like TNF and FasL, TRAIL is also able to induce both 
apoptosis and necrosis (Holler et al., 2000). Death receptor 5 (DR5), the receptor 
for TRAIL, can be expressed by most cells, including adipocytes 
(Fischer-Posovszky et al., 2004). Thus, we tested whether the anti-TRAIL 
treatment would affect the development of panniculitis in LCMV-immune mice after 
VV challenge. As shown in figure 5.6, there was only a minor effect of 
TRAIL-blockade on panniculitis. The levels of panniculitis were slightly (p=0.2) 
decreased in mice treated with anti-TRAIL antibody, compared to control mice. 
Thus, our data suggest that TNF/LT and FasL are the main effector molecules 
contributing to the pathogenesis of panniculitis in VV-infected LCMV-immune mice. 
The low levels of panniculitis generated in gld and etanercept-treated 
LCMV-immune mice after VV challenge may result from the effect of TRAIL. 
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Figure 5.6 TRAIL played a minor role in mediating VV-induced 
panniculitis in LCMV-immune mice. Anti-TRAIL-treated or control WT 
LCMV-immune mice were infected with 1X106 PFU VV IP. Levels of 
panniculitis were recorded at day 6 of infection. Student’s t test was used 
for statistical analysis. 
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C. TNF up-regulates the expression of Fas on adipocytes 
through TNFR2, but not TNFR1. 
The absence of either TNF/LT or FasL completely abolished the incidence of 
panniculitis in LCMV-immune mice during VV infection, suggesting that TNF/LT 
and FasL may be working up or down-stream of each other in the same pathway. 
Many studies have already shown that TNF has many effects on fat cells, such as 
inducing cytokines, cytokine-induced proteins, enzymes and signaling molecules 
(Ruan et al., 2002). It has also been shown that a combined treatment of IFN-γ and 
TNF can up-regulate Fas expression and sensitize human adipocytes for 
Fas-mediated apoptosis (Fischer-Posovszky et al., 2004; Fischer-Posovszky et al., 
2006). To understand how TNF/LT and Fas cooperated with each other to mediate 
panniculitis, we first tested whether the Fas expression on mouse adipocytes 
could be regulated by TNF. Fas mRNA levels were measured in the 3T3-L1 
adipocyte cell line treated with 5ng/mL TNF for 24 hours in the presence or 
absence of antagonistic antibodies against TNFR1 or TNFR2. As shown in figure 
5.7A, after 24-hour stimulation with TNF, the mRNA of Fas was increased about 
60-fold (n=4, paired t test p=0.03). In the presence of antagonistic antibody against 
TNFR1, the enhancement of Fas transcription only slightly decreased from 60-fold 
to 50-fold (p=0.1), but the treatment of antagonistic antibody against TNFR2 
significantly blocked the up-regulation of Fas mRNA in 3T3-L1 adipocytes. In the 
presence of TNFR2 antagonistic antibody, the augmentation of Fas mRNA 
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Figure 5.7 TNF treatments dramatically up-regulated the mRNA 
expression of Fas, but only increased DR5 mRNA mildly. 3T3-L1 
adipocytes 6 days post differentiation induction were treated with 
5ng/mL TNF, with the pretreatment of either 1μg/mL of IgG, TNFR1 
antagonistic antibody or TNFR2 antagonistic antibody. Total RNA was 
isolated 24 hours after treatment and analyzed by quantitative real-time 
PCR for mRNA of Fas (A) and DR5 (B). (n = 4，paired student’s t test 
was used for statistical analysis). 
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reduced from 60-fold to 20-fold after 24-hour treatment with TNF, significantly 
lower than the cells treated with control IgG (n=4, paired t test p=0.048). We also 
tested the up regulation of DR5 by TNF treatment on these adipocytes. The mRNA 
of DR5 only mildly increased 3-fold after 24-hour TNF treatment, and blocking of 
either TNFR1 or TNFR2 alone could not affect this enhancement (Fig 5.7B).  
TNF and LT exert their biological functions through two receptors, TNFR1 and 
TNFR2. The fact that the intracellular sequences of TNFR1 and TNFR2 are largely 
unrelated with almost no homology between each other suggests that TNFR1 and 
TNFR2 may induce different signaling pathways in response to TNF signaling. Our 
data shown in figure 5.7A suggests that it is TNFR2, but not TNFR1 that is 
responsible for regulating Fas expression on adipocytes. To test whether TNFR2 
was involved in mediating panniculitis in LCMV-immune mice during VV infection, 
we adoptively transferred WT LCMV memory splenocytes derived from a single 
donor into one WT naïve host and one TNFR-/- naïve host. Both recipients were 
then infected with 1.0X106 PFU VV IP one day post transfer. As shown in chapter 
IV, the levels of VV-induced panniculitis in LCMV-immune mice was determined by 
the LCMV-specific memory population, as two C57BL/6J hosts receiving the same 
LCMV memory population generated similar levels of panniculitis after VV 
infection (Fig 4.3). If the tested TNF receptor was involved in mediating this effect, 
the TNFR-/- host would show decreased level of disease compared to the WT 
control who received the same donor cells. After VV infection, TNFR2-/- mice 
showed significantly (10 pairs, paired t test p=0.003) diminished pathology, as 
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compared to their WT controls (Fig 5.8A). The decrease in levels of panniculitis in 
TNFR2-/- mice was not due to different levels of viral clearance, as both KO mice 
and WT mice showed similar VV loads in their fat pads and testes (Fig 5.8B). The 
absence of panniculitis was also not because of the failure of donor T cell survival 
in TNFR2-/- mice, since the KO recipients showed comparable numbers of donor 
LCMV-specific CD8 T cells accumulated in peritoneal cavity and fat pads as their 
WT controls (Fig 5.9). To test whether the expression of TNFR2 on the memory T 
cells would also be important for inducing panniculitis, LCMV memory cells derived 
from TNFR2-/- or WT LCMV-immune donors were transferred into WT naïve hosts. 
At day 6 of infection, the recipients receiving TNFR2-/- memory cells generated 
similar levels of panniculitis (Fig 5.10A) and had comparable VV loads (Fig 5.10B) 
as their controls receiving WT memory cells. Therefore, the TNFR2 expression on 
the recipient cells, most likely on the adipocytes, is important for the enhancement 
of VV-induced immunopathology in LCMV-immune mice. 
In contrast to TNFR2-/- mice, TNFR1-/- recipients and WT control mice 
receiving WT LCMV memory cells derived from a single immune donor had 
comparable levels of pathology (10 pairs, paired t test p=0.6) (Fig. 5.11A). 
However, we found TNFR1-/- recipients had higher levels of virus titers in their fat 
pads and testes than their controls, as shown in figure 5.11B. This may affect the 
induction of panniculitis in TNFR1-/- mice, as the death of fat cells may result from 
very high viral loads. Thus it was difficult to conclude whether TNFR1 played a role 
in mediating LCMV-specific memory cell-induced panniculitis during VV infection. 
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Figure 5.8 TNFR2 was required for LCMV immunity mediated
panniculitis during VV infection. Splenocytes from one LCMV-immune 
Ly5.1 mouse were equally adoptively transferred into one naïve WT host 
and one TNFR2-/- host. Both animals were then challenged with 1.0X106
PFU VV IP. A, at day 6 of infection, the levels of panniculitis were 
recorded and compared between TNFR2-/- and WT controls. B shows a 
representative result of virus titers of fat pad and testis. Open bars and 
black bars represent TNFR2-/- hosts and WT controls, respectively. n=5 
per group, error bars represent ±SEM, paired student’s t test was used 
for statistical analysis. 
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Figure 5.9 TNFR2-/- recipients showed comparable numbers of 
donor LCMV-specific CD8 T cells as WT controls. Pooled PEC and 
lymphocytes isolated from fat pads (FP) at day 6 of VV infection were 
examined by ICCS. A representative out of three independent 
experiments is shown.  
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Figure 5.10 TNFR2 expression on the surface of LCMV-specific 
memory T cells was not required for mediating VV-induced 
panniculitis. Splenocytes derived from LCMV-immune TNFR2-/- and WT 
donors were transferred into naïve recipients, respectively. Recipients 
were then infected with 1X106 PFU VV IP. At day 6 of infection, levels of 
panniculitis (A) and VV loads (B) were examined. Student’s t test was 
used for statistical analysis. 
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Figure 5.11 TNFR1-/- recipients showed similar levels of 
panniculitis but higher viral loads than WT control recipients after 
regular dose VV infection. Splenocytes derived from a single WT 
LCMV-immune donor were transferred into one WT and one TNFR1-/-
naïve recipient. Both recipients were then infected with 1X106 PFU VV 
IP. At day 6 of infection, levels of panniculitis (A) and VV loads (B) were 
examined. Paired student’s t test was used for statistical analysis. 
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To test whether the pathology generated in TNFR1-/- mice would be diminished if 
they could control the viral loads to a comparable level to their WT controls, we 
infected TNFR1-/- recipients with a lower dose of VV. One day after transfer of 
LCMV memory cells, TNFR1-/- mice were infected with 6.0X105 PFU VV, while WT 
controls were infected with 1.0X106 PFU VV. At day 6 of infection, the levels of 
panniculitis were recorded, and the virus titers of fat pads and testes were 
examined. With a lower infection dose, TNFR1-/- mice could control the viral loads 
to the same levels as their controls (Fig 5.12B). However, they still showed similar, 
if not increased levels of panniculitis as the WT controls (Fig 5.12A, 5 pairs, paired 
t test p=0.1). A similar experiment was done with the TNFR1-/- recipients receiving 
normal dose (1.0X106 PFU) of VV, and the WT control infected with a higher dose 
of VV (1.5X106 PFU). TNFR1-/- mice still developed comparable levels of 
panniculitis as their WT controls did (data not shown). 
In summary, these results suggest that TNF and LT signal through TNFR2 to 
up-regulate the expression of Fas on the adipocytes. Although TNFR1 can 
mediate programmed necrosis (Holler et al., 2000), it does not seem to be involved 
in the pathogenesis of panniculitis in this model. 
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Figure 5.12 TNFR1 did not play a role in LCMV immunity mediated 
panniculitis during VV infection. Splenocytes derived from a single WT 
LCMV-immune donor were transferred into one WT and one TNFR1-/-
naïve recipient. TNFR1-/- and WT recipients were then infected with
6X105 and 1X106 PFU VV IP, respectively. At day 6 of infection, levels of 
panniculitis (A) and VV loads (B) were examined. Paired student’s t test 
was used for statistical analysis. 
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D. VV infected LCMV-immune mice show increased 
production of TNF by cross-reactive CD8 T cells. 
As shown by a previous study, the fat pads of VV infected LCMV-immune mice 
are infiltrated with activated CD8 T cells specific for LCMV (Selin et al., 1998) 
(Chapter III, Fig 3.1). Adoptive transfer studies showed that the enhanced 
immunopathology was mediated by LCMV memory T cells (Selin et al., 1998). 
Transfer of either CD4 T cells or CD8 T cells from LCMV-immune mice was 
sufficient to induce panniculitis in recipients during acute VV infection (Selin, 
unpublished data), and the level of panniculitis was determined by the memory 
population of the host (Chapter IV). Hence, the cross-reactive LCMV-specific T 
cells play a crucial role in initiating development of panniculitis. Since TNF also 
plays a very important role in mediating this disease as we have shown above, we 
tested whether the production of TNF was different in cross-reactive 
LCMV-specific T cells than primary activated VV-specific T cells. To do so, we 
analyzed the responses against two VV epitopes, VV-a11r198 and e7r130. VV-a11r-
198 is able to elicit a VV-specific T cell response as well as a cross-reactive 
LCMV-specific T cell response. However, e7r130 can only induce a VV-specific 
response, but no cross-reactive response from LCMV-specific memory CD8 T 
cells. We used these two peptides to stimulate the lymphocytes isolated from fat 
pads of VV-infected LCMV-immune and non-immune mice at day 6 of VV infection. 
After a 5-hour in vitro stimulation, epitope-specific cells were gated by IFN-γ 
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production, as shown in figure 5.13. Then IFN-γ+ cells were analyzed for the 
production of TNF. VV-a11r-specific CD8 T cells from LCMV-immune mice 
produced more TNF per cell, compared to a11r-specific cells from non-immune 
mice (Fig. 5.13A and Table 5.1). The increased TNF production was not observed 
when fat pad lymphocytes were stimulated with the non-cross-reactive epitope 
VV-e7r130 (Fig. 5.13B and Table 5.1). Eight independent experiments are shown in 
table 5.1. Although the MFI of TNF varied between experiments, the 
VV-a11r-specific CD8 T cells always had higher TNF production in LCMV-immune 
mice than in non-immune mice in each experiment (paired t test, p=0.02). These 
data suggest that in the fat pads the cross-reactive LCMV-specific CD8 T cells 
produce more TNF than the primary VV effector CD8 T cells upon activation by VV 
epitope.  
However, higher TNF production by the VV-a11r-specific CD8 T cells from 
LCMV-immune mice was not found in PEC or splenocytes (data now shown). 
Increased levels of TNF were also not evident in the serum of LCMV-immune mice 
during VV infection, as compare to non-immune mice (data not shown). However, 
TNF exists both as soluble and membrane-bound form. The assay that we used to 
examine the serum level of TNF could not detect the membrane-bound form of 
TNF. Also the absence of increased TNF in the serum might be explained by the 
fact that the production of TNF was tightly controlled and localized by the extensive 
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Figure 5.13 Cross-reactive memory CD8 T cells produced higher 
levels of TNF, compared to primary effector CD8 T cells. Pooled 
lymphocytes isolated from the fat pads of naïve (doted line) and 
LCMV-immune C57BL/6J (solid line) mice at day 6 of VV infection were 
stimulated with (A) the cross-reactive epitope a11r and (B) the
non-cross-reactive epitope e7r for 5 hours. Cells were then stained for 
CD44, CD8 and for intracellular IFN-γ and TNF. TNF production was 
analyzed on CD8+, CD44+ and IFN-γ+ T cells. 
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Table 5.1 Cross-reactive CD8 T cells produced higher level of TNF than 
non-cross-reactive CD8 T cells at per cell basis (MFI) 
 e7r  a11r 
 Naïve VV  
LCMV 
+VV  
Naïve 
+VV 
LCMV 
+VV¶ 
Experiment 1 40.3 32.4  20.6 115 
Experiment 2 35 225  9.91 811 
Experiment 3 34.8 35.3  7.39 46.1 
Experiment 4 180 184  47.7 329 
Experiment 5 128 67.7  44.7 106 
Experiment 6 623 1092  476 1640 
Experiment 7 2784 4342  2070 3141 
Experiment 8 2236 1903  1383 2804 
Paired t test 0.307  0.017 
 
Lymphocytes isolated from the fat pads of naïve and LCMV immune C57BL/6J
mice at day 6 of VV infection were stimulated with VV peptides for 5 hours, and
then stained for cell CD44, CD8 and for intracellular IFN-γ and TNF. TNF
production (MFI) was analyzed on CD8+, CD44+ and IFN-γ+ T cells. 
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amount of TNFR within the fat tissue (Mohamed-Ali et al., 1999).  
Normally, during VV infection, naïve C57BL/6J mice establish a dominant 
VV-b8r response and sub-dominant VV-e7r response. The response against 
VV-a11r is very limited (Cornberg et al., 2007). However, in a LCMV-immune 
mouse, during VV infection the cross-reactive LCMV-specific memory T cells can 
be activated by the VV epitope, and then selectively expand and be recruited into 
the peritoneal cavity and fat pads, sometimes resulting in an increased a11r 
response (Cornberg et al., 2007; Kim et al., 2005) (Cornberg et al, manuscript 
submitted). These data suggested that LCMV-immune mice may have higher 
levels of TNF　 production in their fat pads at both per cell basis and percentage 
basis than non-immune mice. 
 
E. Chapter summary 
The data shown in this chapter demonstrate the role that TNF/LT and FasL 
play in mediating panniculitis in LCMV-immune mice during VV infection. Both 
TNF/LT and FasL were required to increase the levels of VV-induced panniculitis in 
LCMV-immune mice, since blocking of TNF/LT by etanercept treatment and 
FasL-deficiency completely abrogated the enhancement. On the other hand, 
TRAIL only played a minor role in mediating panniculitis, as the augmentation of 
panniculitis was just partially decreased by the treatment of TRAIL blocking 
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antibody. By transferring LCMV memory cells into WT and TNFNR-/- mice, we 
found that TNFR2, but not TNFR1 was involved in mediating panniculitis. 
Transferring TNFR2-/- LCMV memory cells did not show any effect on the 
pathogenesis of panniculitis, suggesting that the target of TNF/LT was in the 
recipient cells, but not the cross-reactive memory T cells. We also showed that Fas 
mRNA was significantly increased in the mouse adipocyte cell line, 3T3-L1 after 
TNF treatment. Consistent with the results from in vivo experiments, the 
up-regulation of Fas mRNA in the adipocytes was mainly induced by TNFR2 
signaling. We also found that the cross-reactive epitope a11r-specific CD8 T cells 
isolated from LCMV-immune mice produced higher levels of TNF than cells 
isolated from non-immune controls, at single cell basis. This phenomenon was not 
observed when cells were stimulated with VV-e7r, which can not elicit 
cross-reactivity. 
Thus, we conclude that in LCMV-immune mice during VV infection, the 
cross-reactive CD8 T cells produce higher amounts of TNF in the fat pad. Other 
types of cells, such as macrophages may also produce more TNF in response to 
IFN-γ and TNF produced by CD8 T cells. Locally produced TNF may stimulate the 
adipocytes to up-regulate the expression of Fas on their surface. Then Fas may 
directly induce the necrosis of the fat cells and the formation of panniculitis, when it 
interacts with FasL expressed on activated VV-specific and cross-reactive 
LCMV-specific T cells. 
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CHAPTER VI: DISCUSSION 
Based on the effects that TNF has on regulating immune responses, we 
hypothesized that TNF was required for mediating heterologous protection 
against VV in LCMV-immune mice during VV infection. Our data shown in this 
thesis indicate that TNF does not play a role in mediating heterologous protection 
in VV-infected LCMV-immune mice. Although TNF plays a role in limiting VV 
infection in immunologically naïve mice, TNF-deficient (TNF-/- or 
etanercept-treated) LCMV-immune mice are as resistant to VV infection as WT 
LCMV-immune mice (Fig 3.7-3.10). Therefore, prior immunity to LCMV can 
completely abrogate the role of TNF for VV clearance.  
Since TNF is implicated in many human autoimmune diseases, including 
human erythema nodosum (EN), we hypothesized that TNF could contribute to 
the pathogenesis of immunopathology, i.e. panniculitis in VV-infected 
LCMV-immune mice. The data shown in chapter V support our hypothesis, as we 
found the VV-induced panniculitis was significantly diminished in TNF-deficient 
LCMV-immune mice. By testing TNFR-/- mice, we showed that TNFR2, but not 
TNFR1 was involved in mediating VV-induced panniculitis, as the levels of 
panniculitis were significantly decreased in TNFR2-/- mice (Fig 5.8). Furthermore, 
we found that signaling through TNFR2 could dramatically increase Fas mRNA 
expression on mouse 3T3-L1 adipocytes, and FasL-deficiency led to an 
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elimination of this immunopathology in VV-infected LCMV-immune mice. These 
data establish that TNF is involved in the pathogenesis of panniculitis something 
which had been suspected in human disease. Our results reveal a pathway that 
TNF goes through TNFR2 and Fas to induce enhanced fat tissue damage, which 
may be useful for the treatment of human EN or other types of panniculitis, for 
which there is still no definitive treatment. 
The severity of panniculitis is dramatically different among VV-infected 
LCMV-immune mice. It has been shown by our group that the VV-induced 
panniculitis in LCMV-immune mice is mediated by cross-reactive LCMV-specific T 
cells (Selin et al., 1998), and the cross-reactive responses are determined by the 
private specificity of the immune host (Kim et al., 2005). We hypothesized that the 
variation in the levels of panniculitis in VV-infected LCMV-immune mice is 
determined by the private specificity of the memory T cell repertoire. By adoptively 
transferring splenocytes derived from a single LCMV-immune donor into two 
recipients, we were able to show that the levels of immunopathology were similar 
in recipients receiving the same donor cells. However, there were variations in 
recipients receiving different donor cells (Fig 4.3 and Table 4.1). These results 
support our hypothesis, and implicate that the variation in disease outcomes 
following human viral infection may be affected by the unique private specificity of 
the immune memory T cell pool of each individual. Furthermore, we showed that 
recipients receiving a pool of memory T cells with more variety in the TCR 
repertoire tended to develop little pathology, implicating the importance of a 
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diverse TCR repertoire to the host’s safety.  
 
A. Private specificity of memory TCR repertoire determines 
individual variations in the pathology. 
Mice receiving splenocytes derived from a single LCMV-immune donor 
showed significantly less variation in levels of panniculitis after VV challenge than 
mice that received donor splenocytes from different donors (Fig 4.3 and Table 4.1). 
These results indicate that the private specificity of an individual’s unique T cell 
repertoire is the major determinant of the highly variable disease course observed 
in genetically identical LCMV-immune mice during VV infection. It may also 
provide an explanation for the variations in human disease during viral infection, in 
addition to the effect of genetic differences, physiologic conditions and others. 
Since humans are not immunologically naïve, the results of a viral infection can be 
greatly affected by heterologous immunity. The disease course can be ultimately 
variable among individuals, especially in teenagers and young adults, who have a 
longer history of infections and potentially a more complex memory T cell pool than 
young children, and are more likely to be affected by heterologous immunity. 
Some viruses, such as Epstein-Barr virus (EBV), can lead to more severe 
symptoms in teenagers and young adults than in young children, suggesting the 
influences of heterologous immunity in the older group. EBV infects over 90% of 
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the U.S. population. Normally, the primary infection of EBV during childhood is 
asymptomatic. However, primary infection during adolescence frequently 
presents as infectious mononucleosis (IM), a T cell mediated pathology. Older 
adults acutely infected with EBV may have even worse symptoms than young 
adults. They commonly have complications associated with IM, such as 
hepatomegaly, jaundice and fulminant hepatitis (Auwaerter, 1999). Similar to VV, 
EBV is also a large DNA virus and potentially encodes multiple T cell epitopes that 
may elicit cross-reactive T cell responses. As shown previously by our group, a 
subset of T cells with specificity for a HLA-A2.1-restricted immunodominant EBV 
epitope, BMLF-1280-288, can cross-react with influenza A virus (IAV) epitope M158-66 
(Clute et al., 2005). Though IM patients frequently show an increase in the 
number of IAV M1-specific T cells in their blood, this identified cross-reactive 
response between EBV and IAV was only found in some but not all IM patients 
(Clute et al., 2005), which might be a reflection of the uniqueness of private 
specificities of these patients. More cross-reactive T cell responses have been 
identified by our group and a correlation of these cross-reactive responses with 
disease severity has also been found (Aslan, unpublished data). 
Another viral disease that presents with high individual variations in symptoms 
is dengue virus. Dengue is a mosquito-born virus that affects more than 100 
countries, and billions people are at risk of dengue infection. It causes millions to 
be ill and thousands of deaths every year (Gibbons and Vaughn, 2002; Guzman 
and Kouri, 2002). The result of dengue virus infection can range from 
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asymptomatic infection, dengue fever (DF), to dengue haemorrhagic fever (DHF) 
and dengue shock syndrome (DSS). The pathology induced during dengue 
infection is also age related, with none or little symptoms observed in young 
children and more severe diseases developed among older children and adults 
(Gibbons and Vaughn, 2002). Though dengue is a small RNA virus, it has four 
distinct but closely related serotypes. Infection with one serotype provides lifelong 
protection against that serotype, but has heterologous immunities against other 
serotypes (Gibbons and Vaughn, 2002). It is believed that a majority of the cases 
of DHF/DSS is associated with secondary infection by a different serotype of 
dengue (Guzman et al., 2000; Sangkawibha et al., 1984). It may be explained by 
the presence of antibodies that are specifically against the first serotype, 
cross-reactive to the second serotype. Upon binding to the targets, these 
antibodies can not neutralize the virus, but enhance the entry of virus into cells 
(Vaughn et al., 2000). However, a secondary infection is neither sufficient nor 
necessary for a dengue patient to generate severe disease. Since only a small 
number (2-4%) of patients with secondary infection experience DHF/DSS 
(Guzman and Kouri, 2002), and not all DHF/DSS cases are resulted from 
secondary infections (Bravo et al., 1987; Wichmann et al., 2004). Cross-reactive T 
cell responses can also contribute to increased disease severity. It has been 
shown that the selective expansion of cross-reactive T cells with low binding 
affinity for the current infection from the unique memory T cell pool of an individual 
results in inefficient immune response (Mongkolsapaya et al., 2003) and 
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progression to severe forms of disease (Fink et al., 2006).  
Similar to dengue infections, hepatitis C virus (HCV) infections can also 
induce extremely different outcomes between individuals. This small RNA virus 
infects more than a hundred million people worldwide. Though the acute infection 
is frequently asymptomatic, about one third of adults acutely infected show clinical 
symptoms, which vary from mild to severe illness (Urbani et al., 2005). The 
outcomes of HCV infection are also varied from viral clearance to persistent 
infections (Lloyd et al., 2007). Viral-specific CD8 T cell responses are crucial for 
controlling HCV replication. One study suggest that HCV-infected patients with 
more severe pathologies may be associated with a narrowly focused 
cross-reactive response against HCV antigens (Urbani et al., 2005). In this study, 
the two patients with most severe liver pathology showed a cross-reactive 
response between the HLA-A2.1-restricted HCV epitope NS31073-1081 and the IAV 
epitope NA231-239, which is absent in other patients with only mild disease (Urbani 
et al., 2005).  
Collectively, these data and our findings suggest that the pathogenesis of 
immunopathology during viral infections can be greatly influenced by the 
distinctive feature of the memory T cell repertoire of the host. The differences in the 
memory TCR repertoire among individuals determine the presence of variations in 
disease courses and outcomes of infection.  
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B. Divergent TCR repertoire is important for efficient host 
defense. 
The effects of heterologous immunity on the memory T cell repertoire have 
been extensively studied in mice sequentially infected with LCMV and PV 
(Cornberg et al., 2006). The MHC class I Kb-restricted NP205-212 epitopes encoded 
by LCMV and PV have six out of eight amino acids in common, and induce 
cross-reactive responses between these two viruses. As mentioned above, LCMV 
infection of naïve C57BL/6J mice generates a common hierarchy of LCMV-specific 
responses, as the response is co-dominated by NP396 and GP33/34 responses, 
while GP276, NP205 and GP118 responses are subdominant (see Introduction). 
Infection with LCMV also results in a dominant usage of the Vβ16 family by 
NP205-specific CD8 T cells, which show a broad clonotype usage. However, as 
shown in figure 6.1, heterologous challenge of LCMV-immune mice with PV leads 
to an enhanced expansion of the usually subdominant cross-reactive 
NP205-specific population. This is associated with oligoclonal expansion of other 
Vβ families and a narrowing down of the clonotypes used within these families 
(Cornberg et al., 2006; Welsh et al., 2006). These changes are resulting from the 
selective expansion of the memory T cells that are cross-reactive to PV and the 
attrition of the non-cross-reactive ones (Brehm et al., 2002; Cornberg et al., 2006; 
Selin et al., 1999). Skewing of the TCR repertoire during heterologous immunity 
was also reported in human EBV infections (Clute et al., 2005). The cross-reactive 
 
117 
 
Fi
gu
re
 6
.1
 M
od
ul
at
io
n 
of
 t
he
 T
-c
el
l 
re
pe
rt
oi
re
 d
ur
in
g 
he
te
ro
lo
go
us
 v
ira
l 
in
fe
ct
io
n.
 D
iff
er
en
t 
do
ts
 
re
pr
es
en
t 
T-
ce
lls
 w
ith
 d
iff
er
en
t 
sp
ec
ifi
ci
tie
s.
 A
 n
ai
ve
 im
m
un
e 
sy
st
em
 c
ha
lle
ng
ed
 w
ith
 e
ith
er
 L
C
M
V
 o
r 
PV
 
sh
ow
s 
ex
pa
ns
io
ns
 o
f 
vi
ru
s-
sp
ec
ifi
c 
T 
ce
lls
. 
W
he
n 
th
e 
in
fe
ct
io
n 
is
 r
es
ol
ve
d,
 s
om
e 
of
 t
he
se
 c
el
ls
 u
nd
er
go
 
ap
op
to
si
s.
 I
f 
an
 im
m
un
e 
sy
st
em
 t
ha
t 
ha
s 
be
en
 c
on
di
tio
ne
d 
by
 o
ne
 v
iru
s 
in
fe
ct
io
n 
(L
C
M
V
) 
is
 e
xp
os
ed
 t
o 
an
ot
he
r 
vi
ru
s 
(P
V
), 
T-
ce
ll 
po
pu
la
tio
ns
 th
at
 a
re
 c
ro
ss
-r
ea
ct
iv
e 
w
ith
 th
e 
tw
o 
vi
ru
se
s 
(r
ed
 o
ut
lin
e)
 w
ill
 e
xp
an
d 
pr
ef
er
en
tia
lly
 a
nd
 d
om
in
at
e 
th
e 
re
sp
on
se
, w
hi
le
 th
e 
m
em
or
y 
T 
ce
lls
 th
at
 a
re
 s
pe
ci
fic
 fo
r 
th
e 
fir
st
 v
iru
s 
ar
e 
re
du
ce
d 
in
 n
um
be
r, 
w
hi
ch
 re
su
lts
 in
 a
 s
ke
w
in
g 
in
 th
e 
hi
er
ar
ch
y 
of
 th
e 
T 
ce
ll 
re
sp
on
se
 a
ga
in
st
 th
e 
fir
st
 v
iru
s.
 
Th
is
 fi
gu
re
 w
as
 ta
ke
n 
fro
m
 W
el
sh
 a
nd
 S
el
in
 2
00
2 
N
at
 R
ev
 Im
m
un
ol
 2
: 4
17
-4
26
. 
 
118 
response between IAV-M1 and EBV-BMLF1 induced a skewed hierarchy of Jβ 
usage by IAV-M1-specific CD8 T cells. In healthy IAV immune donors, the Jβ 
usage of the Vb17+ M1-specific CD8 T cells was dominated by Jβ2.7 (55-62%) 
followed by Jβ2.3 (10-20%), and Jβ2.1, 2.5, 1.1 and 1.2 were present at lower 
frequencies (Naumov et al., unpublished observation). However, in Clute’s study 
the two patients with EBV-associated IM showed substantial changes in the 
hierarchies of Jβ usage by M1-specific Vβ17+ CD8 T cells. In one patient, Jβ1.2 
family was predominantly used by about 50% of these cells. An increased Jβ2.3 
family (30%) and decreased Jβ2.7 family (10%) usage was seen in another patient 
(Clute et al., 2005). Thus, sequential infections tend to narrow down the TCR 
repertoire by selectively expanding a small subset of cross-reactive T cells. 
However, the dramatically narrowed TCR repertoire may be not able to provide 
efficient protection against infections the host will experience in the future. 
A diverse T cell response is helpful for the host to provide better protection 
than a narrowly focused T cell response. Such as during HCV infection, vigorous 
CD8 T cell responses specific to multiple HCV epitopes are associated with viral 
clearance. However, the HCV-specific CD8 T cell responses found in chronically 
infected patients and animals are usually weak and narrowly focused (Lloyd et al., 
2007). One explanation for the inefficient protection mediated by narrowly focused 
T cell response is the escape mutation of the virus (Cornberg et al., 2006). When 
PV-immune mice were infected with 2X105 PFU of LCMV (clone 13), they 
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established persistent LCMV infection and a narrowed NP205-specific CD8 T cell 
repertoire. Eight months after LCMV clone 13 inoculation, a variant with a mutation 
from valine to alanine in the third position of the LCMV-specific NP205 epitope was 
found (Cornberg et al., 2006). Although this mutant peptide could bind to MHC-Kb 
molecule and present to the T cells, it was less efficient than WT NP205 epitope in 
inducing IFN-γ production by CD8 T cells isolated from LCMV-infected naïve or 
PV-immune mice (Cornberg et al., 2006).  
The scope of the T cell repertoire may greatly affect the result of an infection. 
As shown in Chapter IV, when mice were transferred with pooled splenocytes from 
multiple LCMV-immune donors, only 20% of the mice (3 out of 14) showed 
moderate to severe levels of panniculitis. However, when mice received 
splenocytes derived from one donor, about 40% (15 out of 38) of the mice showed 
moderate to severe levels of panniculitis after VV infection (Fig 4.3B, Table 4.1). 
Since every LCMV-immune mouse has a distinct memory T cell repertoire, the 
pooled splenocytes derived from multiple LCMV-immune donors have a more 
diverse TCR repertoire than splenocytes from a single donor. A recipient that 
obtained a diverse TCR repertoire will have a greater chance of eliciting a 
beneficial cross-reactive T cell response.  
Highly skewed or focused T cell responses can be dangerous. This is 
because they do not provide efficient immune surveillance, and may not generate 
efficient cross-reactive T cell responses, which may mediate severe tissue 
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damage. Our results have strong application for vaccine designs. For example, an 
attenuated vaccine may induce a broad T cell response to multiple epitopes, which 
will provide better protection against this pathogen. Vaccines that focus on a single 
T cell epitope of a pathogen might be risky and should be avoided, because the 
resulting memory T cell response would not be able to clear an unrelated pathogen 
efficiently and result in severe tissue damage (Welsh and Fujinami, 2007). 
 
C. The role of TNF in mediating protective immunity and 
immunopathology 
Secreting cytokines is one of the most important effector functions CD8 T cells 
play to control viral infections, such as LCMV (Klavinskis et al., 1989), VV (Chan et 
al., 2003; Lidbury et al., 1995; Ruby et al., 1997; Sambhi et al., 1991), hepatitis B 
virus (HBV) (Kasahara et al., 2003), herpes simplex virus (Bouley et al., 1995), 
respiratory syncytial virus (RSV) (Ostler et al., 2002) and EV (Ruby et al., 1997). 
Exposure to cytokines can directly reduce viral replication, increase MHC class I 
expression and up-regulate cellular genes known to increase resistance to viral 
infection (Slifka and Whitton, 2000b). However, the production of inflammatory 
cytokines in response to infection may result in development of immunopathology.  
As shown in Chapter III, neither IFN-γ nor TNF/LT was important for the 
selective expansion and recruitment of cross-reactive LCMV-specific CD8 T cells 
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in VV-infected LCMV-immune mice (Fig 3.1, 3.3 and 3.4). However, previous 
studies by our group have shown that IFN-γ produced by cross-reactive 
LCMV-specific memory T cells is required for mediating both heterologous 
protective immunity against VV and VV-induced immunopathology (Chen et al., 
2001; Selin et al., 1998). The absence of TNF and LT did not affect the 
heterologous protection against VV provided by LCMV immunity; although it 
substantially diminished the levels of immunopathology (Fig 5.1). This suggests 
that TNF and LT signaling plays a role in pathogenesis of panniculitis in 
LCMV-immune mice challenged with VV.  
This is supported by data from a mouse RSV model. When mice were infected 
with RSV, they could clear virus, but developed severe lung injury. IFN-γ produced 
by virus-specific CD8 T cells was required for both viral clearance and 
immunopathology (Ostler et al., 2002). On the other hand, TNF played a major 
effect on mediating immunopathology associated with RSV and influenza, but only 
a minor role in antiviral activity (Hussell et al., 2001; Ostler et al., 2002; Rutigliano 
and Graham, 2004).  
Since TNF is important in mediating immunopathology during multiple viral 
infections, it is important to understand its source. In 2006, Liu et al. reported that 
the administration of cognate synthetic peptides to mice, that were either acutely 
infected or long-term immune, could cause intestinal pathology. The pathogenic 
effects of the peptide vaccine were dependent on the presence of epitope-specific 
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CD8 T cells, because pathology was not seen in CD8 T cell-depleted mice or naïve 
mice after injection of peptide. Since TNFR1-/- mice did not show signs of illness 
after peptide injection, TNF was also suggested to be involved in the pathogenesis 
of this pathology. When the authors further examined the TNF producing cells, 
they found that most of the TNF+ cells were also CD8+. Therefore, the data of this 
study suggest that the peptide-induced symptom is dependent on TNF production 
by the large pre-existing pool of epitope-specific CD8 T cells (Liu et al., 2006). 
Consistent with Liu’s study, we found the presence of cross-reactive 
LCMV-specific memory T cells and TNF were also responsible for the 
pathogenesis of panniculitis in VV-infected LCMV-immune mice. These 
cross-reactive LCMV-specific memory T cells are present at higher frequency than 
the naïve VV-specific precursors. Memory cells can also respond to antigen more 
quickly and stronger than naïve cells, and may cause a highly inflammatory 
environment. In such a situation, a large amount of TNF might be produced by 
activated T cells as well as macrophages. By comparing TNF production by 
antigen-specific CD8 T cells, we found that VV-a11r-specific CD8 T cells isolated 
from the fat pads of VV-infected LCMV-immune mice produced higher levels of 
TNF than cells isolated from non-immune mice. However, there was no difference 
in TNF production by VV-e7r-specific CD8 T cells isolated from the fat pads of 
VV-infected LCMV-immune and non-immune mice (Fig 5.13 and Table 5.1). The 
difference between these two VV epitopes is that VV-a11r can elicit cross-reactive 
response from LCMV-specific memory CD8 T cells, but VV-e7r can not. From this, 
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we concluded that the reactivated cross-reactive LCMV-specific CD8 memory T 
cells produced higher amounts of TNF than VV-specific CD8 T cells. This is 
consistent with the data shown by Slifka et al. that memory CD8 T cells produced 
more TNF than primary effector CD8 T cells after direct ex vivo stimulation with 
peptide (Slifka and Whitton, 2000a). Collectively, our data indicate that TNF has no 
effect on controlling VV infection during heterologous challenge in LCMV-immune 
mice. However, the increased expression of TNF in the fat pads is involved in 
immunopathology.  
Although TNF can interact with two receptors, most of the biologic functions of 
TNF were ascribed to TNFR1. Surprisingly, in this thesis research we found that it 
was TNFR2, independent of TNFR1 that was involved in the pathogenesis of 
panniculitis in LCMV-immune mice during VV infection (Fig 5.8). Our data are 
consistent with Douni and Kollias’ finding that TNFR2 plays a critical role in 
multi-organ inflammation (Douni and Kollias, 1998). They found that at levels 
relevant to human disease, the production of human TNFR2 (hTNFR2) in 
transgenic mice could trigger the inflammation in multiple organs, resulting in 
shorten lifespan. This process was TNFR1-independent, as TNFR1-/- mice 
expressing hTNFR2 at high level had a shortened lifespan similar to WT mice 
expressing hTNFR2. An association of TNFR2 and human autoimmune disease 
has also been suggested. It has been reported that TNFR2 196R, a more effective 
polymorphism of TNFR2, is associated with familial rheumatoid arthritis (Dieude et 
al., 2002) and systemic lupus erythematosus (Komata et al., 1999). Collectively, 
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these data and our results suggest TNFR2 may have a unique role in causing 
inflammation and tissue damage. 
  
D. Pathogenesis of panniculitis in LCMV-immune mice during 
VV infection and its implication for human disease.  
Considering to the importance of TNF in regulating immune responses and its 
association with human autoimmune disease, we hypothesized that TNF would be 
required for mediating heterologous protection against VV and immunopathology 
in VV-infected LCMV-immune mice. Our data shown in this thesis confirm our 
hypothesis and demonstrate a pathway that TNF goes through to mediate 
VV-induced fat tissue damage in LCMV-immune mice (Fig 6.2). During VV 
infection, antigen presenting cells (APC) present VV epitopes to T cells. In 
LCMV-immune mice, the LCMV-specific memory T cells that are cross-reactive to 
VV-epitopes re-activate and accumulate in the sites of infection, such as fat pads. 
These cells then rapidly start to produce high levels of IFN-γ (Chen et al., 2001) 
and TNF (Fig 5.13) . IFN-γ production not only eliminates VV infection efficiently, 
but also increases inflammation by activating the APC to produce more TNF. TNF 
and LT signal through TNFR2 on adipocytes and induce the up-regulation of Fas 
expression. When Fas engages its ligand on activated VV-specific T cells and 
cross-reactive LCMV-specific T cells, it induces the necrosis of fat cells and causes 
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panniculitis. In the whole process, TNF does not play a role in clearing VV from 
LCMV-immune mice, since the clearance of VV in etanercept-treated 
LCMV-immune mice is as efficient as control LCMV-immune mice. 
Our finding implicates one possible mechanism for the pathogenesis of 
panniculitis associated with human infections. During infection or vaccination, the 
reactivated pre-existing cross-reactive memory T cells may mediate a strong 
inflammatory response with increased cytokine production. These cytokines then 
go through autocrine as well as paracrine signaling to induce more cytokine 
production. For instance, IFN-γ activates macrophages to produce more TNF, and 
TNF works on NK cells and cross-reactive T cells to increase IFN-γ production. As 
mentioned earlier, TNF can induce inflammatory cytokine production by 
adipocytes, including IFN-β and IL-6 and leptin (Ruan et al., 2002). In turn, leptin is 
also known to positively regulate the production of TNF, IL-6 and IL-12 by 
macrophages (Matarese et al., 2007). Thus, as a consequence of these feedback 
loops, the host will experience a cytokine storm. During this uncontrollable 
inflammatory condition, Fas is up-regulated on the surface of adipocytes. Upon 
interaction of Fas with FasL, which is expressed on activated T cells in the adipose 
tissue, necrosis of adipocytes occurs. 
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E. Safety of anti-TNF treatment in humans 
The inappropriate production of TNF has been reported to be involved in 
many types of human autoimmune diseases, such as type II diabetes mellitus, 
rheumatoid arthritis (RA) and chronic heart failure (Aggarwal, 2003). An 
association of TNF with human EN has been suggested since anti-TNF treatment 
efficiently improves the symptoms of EN (see Introduction). In this thesis, we 
showed that the VV-induced panniculitis was completely abolished by treatment 
with etanercept (Fig 5.1 and 5.2). Additionally, the levels of panniculitis were 
significantly reduced in TNFR2-/- hosts, compared to the WT controls (Fig 5.8). 
These data directly show that TNF and LT are involved in the pathogenesis of 
panniculitis in LCMV-immune mice during VV infection. According to our data, we 
suggest that anti-TNF therapy may be considered as a treatment for human EN or 
other types of panniculitis, for which at the present time there is no definitive 
therapy.  
Worldwide about half million patients have received anti-TNF treatment. It has 
been shown that anti-TNF therapies are very effective for treatment of Crohn’s 
disease (Present et al., 1999; Suenaert et al., 2002) and RA (Bathon et al., 2000; 
Feldmann and Maini, 2001). However, the concern of using anti-TNF treatment is 
that it can be associated with an increased risk of developing serious infections, 
due to the important role that TNF plays in regulating immune responses (Desai 
and Furst, 2006; Ellerin et al., 2003). TNF has been reported to be required for 
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normal innate and adaptive immune response (see instruction and Table 6.1) and 
play essential roles in host defense against many pathogens, such as 
mycobacterium tuberculosis (Flynn et al., 1995), HBV (Kasahara et al., 2003), and 
HIV (Herbein et al., 1996). So it is not surprising that disruption of TNF function 
may increase the susceptibility of the host to certain pathogens. However, 
according to the data collected from clinical trial and post-marketing analysis, the 
treatment with TNF blocking reagents is relatively well tolerated (Calabrese et al., 
2004; Desai and Furst, 2006). There is only a slight increase in the risk of 
non-serious infections and no consistent evidence suggesting an increased risk in 
serious infections. As mentioned previously, TNF plays a role in decreasing HBV 
replication (Desai and Furst, 2006; Guidotti et al., 1996), so the blocking of TNF 
signal may lead to the increase of viral loads in patients with chronic HBV infection. 
Indeed, among eleven HBV patients who have been treated with anti-TNF 
therapies, only two patients show reactivation of HBV (Desai and Furst, 2006). 
Additionally, HIV patients receiving anti-TNF treatment also showed a very low 
frequency of increase in viral loads. One study reported that sixteen out of 
seventeen HIV patients receiving single dose of anti-TNF reagent showed no 
effect on either plasma HIV RNA level or CD4 T cell counts. Another report of 13 
patients with HIV and active TB showed that a 4-week anti-TNF treatment had no 
effect on these patients, either. However, one out of three HIV patients with RA 
receiving anti-TNF treatment experienced repeated infection, although the CD4 T 
cell counts and HIV RNA level were stable during the treatment. The difference 
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Table 6.1 Influences of TNF on immune cells 
 
Monocyte/ macrophages 
  Activate 
  Autoinduce TNF-α 
   Chemotaxis and migration 
  Inhibit differentiation 
  Suppress proliferation 
Lymphocytes   
  Induce T cell colony formation 
  Induce superoxide in B cells 
  Induce apoptosis in mature T cells 
  Activate cytotoxic T cell invasiveness 
 
This table is adapted from Ellerin 2003 Arthritis Rheum. 48:3013-22 
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between this patient and the other two was that this patient had advanced HIV 
infection with CD4 T cell counts less than 50/mm3 (Calabrese et al., 2004). 
Therefore, an immune system with a normal T cell pool is very important for 
controlling infections during anti-TNF treatment. 
Our data shown here indicate that although TNF is important for naïve mice to 
control VV infection, the heterologous protective immunity mediated by 
LCMV-immunity completely compensates the need for TNF on defending against 
VV infection. This result implies that the anti-TNF therapies in treating various 
human diseases may be relatively safe, perhaps in large part due to heterologous 
immunity. Humans are exposed to many pathogens throughout their lives and 
have a large complex pool of memory T cells that have the potential to cross-react 
with any new pathogen and mediate heterologous protective immunity. 
 
F. Future direction 
Our data shown above suggest that Fas/FasL signaling is responsible for the 
generation of panniculitis in LCMV-immune mice during VV infection. In the future 
we want to test whether panniculitis in VV-infected LCMV-immune mice is induced 
exclusively by FasL expressed on the cross-reactive LCMV-specific memory T 
cells. To test this possibility, we can adoptively transfer CFSE-labeled splenocytes 
from one LCMV-immune gld mouse into one WT and one gld naïve host. At the 
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same time, splenocytes derived from one WT LCMV-immune mouse will be 
transferred into one WT and one gld host. All hosts will then be challenged with VV. 
At day 6 of infection, we will determine the proliferation of LCMV-specific T cells by 
loss of CFSE label, and record the levels of panniculitis in these hosts. According 
to our data (Fig 5.4A), gld hosts that received gld LCMV-immune cells will have no 
increased levels of panniculitis, while WT hosts receiving WT donor cells will show 
enhanced panniculitis. By comparing the levels of panniculitis shown in gld hosts 
receiving WT donor cells and WT hosts receiving gld donor cells to these two 
control groups respectively, we should be able to tell whether the expression of 
FasL on activated VV-specific T cells is also involved in the pathogenesis of 
panniculitis. 
To further understand why cross-reactive LCMV-specific memory T cells can 
induce altered immunopathology during VV infection, we would like to test two 
possibilities. First, compared to VV-specific memory T cells, cross-reactive 
LCMV-specific memory T cells may have lower affinity to VV antigens and result in 
a not very efficient protection (partial protection) but strong inflammation, which 
leads to the generation of panniculitis. To test whether LCMV-immune memory 
cells can induce higher levels of inflammation, we can first test the levels of 
inflammatory cytokines, such as IL-1, IL-6 and TNF, as well as immune regulatory 
cytokines, including IL-10, TGF-β and IL-17 in the fad pads and serum of 
VV-infected hosts that are transferred with either LCMV-immune cells or 
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VV-immune cells. We can also test whether there is a correlation between the 
levels of those cytokines and panniculitis. To test whether the pathogenesis of 
panniculitis is due to inefficient protection during early VV infection, we can transfer 
LCMV memory T cells from one single donor into two naïve hosts. According to the 
data shown in Chapter IV, we can suppose these two naïve hosts will have similar 
levels of panniculitis. One of the hosts will be used to test VV loads at day 3 of VV 
infection, while the other one will be sacrificed at day 6 of infection to record the 
levels of panniculitis. With a number of donor-recipient pairs, we should be able to 
find whether there is a correlation between the VV titer (day 3) and levels of 
panniculitis (day 6). To directly test whether the pathogenesis of panniculitis is 
caused by cross-reactive memory T cells with lower affinity, at day 6 of VV infection, 
the lymphocytes will be isolated from multiple organs of LCMV-immune mice. As 
we mentioned earlier, VV-a11r can induce cross-reactive responses from T cells 
that are specific to LCMV-GP34, NP205 or GP118. Isolated cells will be double 
stained with VV-a11r tetramer and LCMV-GP34, NP205 and GP118 tetramer, 
respectively. The MFI of VV-a11r will be evaluated in the double positive 
cross-reactive T cell populations. If panniculitis is mediated by lower affinity 
cross-reactive LCMV memory T cells, the mouse that generates higher levels of 
panniculitis will have lower MFI of VV-a11r in the cross-reactive CD8 T cell 
population. 
Another possible explanation for the induction of panniculitis in 
LCMV-immune mice during VV infection is that there is a pathogenic 
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cross-reactive response selectively expanded. After analyzing more than one 
hundred VV-infected LCMV-immune mice, we found there was a very slight trend 
that mice using NP205 cross-reactive response tend to have lower levels of 
panniculitis (data not shown). To test whether there is a pathogenic epitope 
responsible for the pathogenesis of panniculitis, we can immunize mice with 
different LCMV variants and test the levels of pathology in these mice after VV 
infection. There is one LCMV variant (GPNPV) having partial deletions of their 
responses to all four dominant epiotpes (NP396, GP33/34, GP207). There is also 
a LCMV-NP205 variant with a single mutation within the NP205 epitope, which 
leads to a decreased NP205-specific response in mice immunized with this variant. 
After immunizing mice with LCMV or its variants, these mice will be challenged 
with VV and the levels of panniculitis will be recorded at day 6 of infection. The 
levels of proliferation of T cells that are specific to all five LCMV epitopes will be 
examined. If there is a pathogenic epitope, there will be a correlation between the 
levels of panniculitis and the levels of the proliferation of T cells specific to that 
pathogenic epitope. To further confirm this observation, mice can be immunized 
with different LCMV peptides and then challenged with VV. The mice immunized 
with the pathogenic epitope will tend to have higher levels of panniculitis, while the 
mice immunized with the non-pathogenic epitope will show lower levels or no 
panniculitis. 
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